The O
most O
important O
biomarkers O
which O
contribute O
to O
the O
model O
were O
Cis-11-Eicosenoic O
(C20:1n9), O
Lauric O
acid O
(C12:0), O
Erucic O
acid O
(C22:1n9), O
Cis-10-pentadecanoic O
acid O
(C15:1), O
Stearic O
acid O
(C18:0), O
Myristic O
acid O
(C14:0), O
FA B-lipid
17:0 I-lipid
(C17:0), O
FA B-lipid
16:0 I-lipid
(C16:0). O

Additionally, O
we O
searched O
for O
a O
correlation O
between O
SL O
metabolites O
and O
key O
AERD O
biomarkers, O
FA B-lipid
20:4;15OH I-lipid
(15-HETE), O
human O
leukocyte O
antigen O
HLA-DBP1*0301 O
, O
cysteinyl O
leukotriene O
receptor O
type O
1 O
(CYSLTR1) O
gene O
polymorphism O
and O
periostin. O

Concretely, O
for O
the O
compounds O
m-cresol, O
3-heptanone, O
benzene, O
4-methyl-2-heptanone, O
acetone, O
1-propanol, O
FAL B-lipid
9:0, I-lipid
4-tert-butylphenol, O
phenol, O
3-methyl-2-heptanone, O
dimethyl O
trisulfide, O
2-methyl-5- O
(methylthio) O
furan, O
FAL B-lipid
7:0, I-lipid
dimethyl O
disulfide, O
2-methylthiophene, O
tetrahydro-2, O
2-dimethyl-5-(1-methyl-1-propenyl) O
furan, O
2-methyl-butyric O
acid, O
styrene, O
2-ethylfuran, O
ethylbenzene O
and O
thiophene O
were O
determined O
significantly O
higher O
levels O
in O
the O
urine O
of O
the O
patient O
population. O

Of O
all O
the O
molecules O
studied O
related O
to O
platelet O
activation O
pathway, O
we O
found O
that O
only O
FA B-lipid
20:4;OH I-lipid
had O
increased O
plasma O
levels O
in O
patients O
who O
underwent O
carotid O
endarterectomy. O

In O
contrast, O
ceramide O
(Cer) O
Cer B-lipid
18:1;O2/21:0 I-lipid
and O
Cer B-lipid
18:2;O2/23:0, I-lipid
ursodeoxycholic O
acid O
(UDCA), O
and O
the O
ratios O
BCAA O
to O
ArAA, O
and O
BCAA O
to O
tyrosine O
(BTR) O
decreased O
along O
with O
the O
fibrosis O
stages O
of O
the O
studied O
patients O
(absolute O
PCC > 0.98). O

We O
found O
that O
Valine, O
Sphingomyeline O
C24:1, O
Lysine, O
Histidine, O
Tryptophan, O
Octadecenoylcarnitine, O
Tripentadecanoate O
TG15, O
LysoPhosphatidylcholine O
acyl O
C20:3, O
FA B-lipid
22:6, I-lipid
Sphingomyeline O
C18:1, O
LysoPhosphatidylcholine O
acyl O
C20:4, O
Phosphatidylcholinediacyl O
C32:0, O
Symmetric O
dimethylarginine, O
Glycoursodeoxycholic O
Acid, O
1monopalmitoleoyl-rac-GL1, O
G-LCA, O
LysoPhosphatidylcholine O
acyl O
C18:0 O
were O
the O
most O
important O
predictors O
of O
one O
year O
mortality O
risk O
(as O
shown O
in O
Figure O
reporting O
from O
the O
most O
to O
the O
less O
important). O

Changes O
in O
lactosylceramide O
correlated O
positively O
with O
△ O
decanoylcarnitine O
and O
negatively O
with O
△ O
L-valine, O
△ O
lysoPCs O
(14:0, O
16:0, O
18:2, O
18:0, O
20:3, O
and O
22:6), O
and O
△ O
PC B-lipid
18:0/20:4 I-lipid
(r O
= O
0.266, O
P O
= O
0.004). O

Altered O
levels O
of O
some O
of O
the O
oxylipins, O
especially O
in O
certain O
monohydroxy O
fatty O
acids O
such O
as O
FA B-lipid
20:4;OH I-lipid
and O
FA B-lipid
20:5;OH, I-lipid
were O
observed O
in O
samples O
collected O
before O
and O
24 h O
after O
cardiac O
surgery. O

The O
inter-run O
precision O
was O
in O
the O
range O
of O
3.2%CV O
and O
3.6%CV O
for O
Cer B-lipid
22:0;O2 I-lipid
and O
Cer B-lipid
24:0;O2, I-lipid
respectively. O

From O
our O
study, O
the O
observed O
progressive O
decrease O
in O
the O
concentration O
levels O
of O
AA, O
DHA, O
DPA, O
lysophospholipids O
and O
their O
downstream O
products O
such O
as O
FA B-lipid
20:3 I-lipid
after O
reperfusion O
strongly O
endorses O
the O
possible O
part O
that O
PLA_2 O
plays O
in O
disturbed O
phospholipid O
homeostasis O
during O
the O
transition O
from O
reversible O
to O
irreversible O
ischemic O
myocardial O
injury. O

Such O
new O
roles O
include O
gene O
regulation: O
PC B-lipid
16:0/18:1 I-lipid
have O
been O
described O
as O
an O
endogenous O
ligand O
for O
the O
nuclear O
receptor O
PPAR O
alpha O
in O
hepatocytes, O
a O
transcription O
factor O
regulating O
the O
expression O
of O
many O
genes O
that O
govern O
lipid O
metabolism. O

In O
addition, O
Ward O
et O
al. O
suggested O
that O
FA B-lipid
20:4;OH I-lipid
plays O
a O
role O
in O
the O
pathophysiology O
of O
acute O
ischaemic O
stroke O
and O
subsequent O
clinical O
outcome. O

Ang O
II O
can O
activate O
the O
release O
of O
renal O
FA B-lipid
20:4;OH I-lipid
by O
stimulating O
the O
synthesis O
of O
FA O
20:4;OH O
at O
critical O
sites O
in O
the O
kidney: O
the O
preglomerular O
microvessels O
that O
determine O
renovascular O
resistance O
and O
a O
nephron O
segment, O
the O
medullary O
thick O
ascending O
limb, O
that O
contributes O
decisively O
to O
salt O
and O
water O
balance. O

However, O
it O
is O
still O
noticeable O
that O
PC B-lipid
40:7 I-lipid
is O
so O
abundant. O

Specifically, O
we O
found O
that O
levels O
of O
PC B-lipid
15:0/22:6, I-lipid
arachidonic O
acid, O

The O
proportion O
of O
PUFA-enriched O
LPC B-lipid
22:6 I-lipid
was O
positively O
associated O
with O
HDL O
(r O
= O
0.53, O
p O
= O
0.02) O
and O
inversely O
associated O
with O
TG O
levels O
(r O
= O
−0.45, O
p O
= O
0.05). O

Three O
sphingolipids, O
Cer B-lipid
18:1;O2/23:0, I-lipid
SM B-lipid
18:1;O2/14:0, I-lipid
SM B-lipid
18:2;O2/14:0 I-lipid
were O
decreased O
in O
EOC O
recurrent O
patients. O

However, O
there O
is O
also O
co-elution O
of O
neutral O
and O
lipid O
compounds; O
testosterone-d_2 O
co-eluted O
with O
17:0 O
Cer, O
and O
PC B-lipid
19:0/15:1 I-lipid
co-eluted O
with O
an O
unknown O
compound O
with O
a O
similar O
m/ O

(B O
) O
PA B-lipid
32:0 I-lipid
levels O
increase O
in O
primary O
fibroblasts O
with O
time O
after O
infection O
with O
HCMV. O

From O
65 O
differential O
lipids O
highlighted O
between O
responder O
(RP) O
vs O
not O
responder O
(NRP) O
patients, O
five O
lipids O
were O
validated O
to O
predict O
response O
at O
T0: O
SM B-lipid
18:2;O2/18:1, I-lipid
LysoPC O
(16:0/0:0), O
LysoPC O
(15:1(9z)/0:0), O
Lyso O
LPE B-lipid
22:5/0:0 I-lipid
and O
m/z= O
842.90 O
corresponding O
to O
a O
PC O
containing O
2 O
fatty O
acids O
of O
40 O
carbons O
totally. O

FA B-lipid
5:0, I-lipid
FA B-lipid
20:1(11), I-lipid
pentaenoate O
showed O
increased O
while O
UDP O
showed O
decreased O
abundance O
in O
both O
tissue O
and O
serum O
samples O
of O
IDC O
when O
compared O
to O
control. O

The O
catabolic O
pathways O
of O
branched O
chain O
amino O
acids O
(BCAAs) O
are O
analogous O
to O
the O
fatty O
acid O
oxidation O
pathway, O
and O
can O
be O
utilised O
for O
lipid O
synthesis, O
since O
all O
three O
BCAA O
pathways O
ultimately O
generate O
CoA B-lipid
3:0 I-lipid
and/or O

One O
example O
is O
shown O
in O
, O
where O
an O
examination O
of O
the O
space O
defined O
by O
the O
precursor O
ion O
m/z O
and O
drift O
time O
reveals O
the O
chromatographic O
coelution O
of O
a O
phosphatidylcholine, O
PC B-lipid
36:1, I-lipid
and O
two O
sphingomyelins, O
SM B-lipid
40:2;O2 I-lipid
and O
SM B-lipid
38:1;O2. I-lipid

The O
absolute O
concentration O
(ng/mL) O
of O
each O
PC O
was O
calculated O
based O
on O
the O
peak O
area O
of O
the O
PC O
identified O
in O
the O
sample O
and O
the O
peak O
area O
of O
the O
internal O
standard O
of O
PC B-lipid
15:0/18:1 I-lipid
corresponding O
to O
the O
sample O
(the O
formula O
was O
shown O
in O
Figure _S1 O
). O

The O
pressor O
response O
to O
increases O
in O
circulating O
Ang O
II O
can O
be O
attenuated O
by O
inhibition O
of O
FA B-lipid
20:4;OH I-lipid
synthesis. O

details O
the O
mean, O
median O
and O
range O
of O
membrane O
fatty O
acid O
concentrations O
as O
assessed O
by O
mass O
spectrometry, O
including O
arachidonic O
acid O
(AA), O
alpha O
linolenic O
acid O
(ALA), O
FA B-lipid
20:5 I-lipid
(EPA), O
docosahexanoic O
acid O
(DHA), O
total O
omega O
6 O
acid O
and O
total O
omega O
3 O
acid. O

The O
stability O
of O
Cer B-lipid
22:0;O2 I-lipid
and O
Cer B-lipid
24:0;O2 I-lipid
were O
determined O
to O
be O
acceptable O
in O
human O
plasma O
following O
five O
freeze–thaw O
cycles. O

A O
100 O
μl O
aliquot O
of O
serum O
sample O
was O
spiked O
with O
two O
internal O
standards O
(10 O
μl O
l-2-chlorophenylalanine O
in O
water, O
0.3 O
mg/ml; O
10 O
μl O
FA B-lipid
17:0 I-lipid
in O
methanol, O
1 O
mg/ml) O
and O
vortexed O
for O
10 O
s. O

We O
observed O
significantly O
increased O
levels O
of O
FAs O
(FA O
14:0, I-lipid
FA(14:1)-1, O
FA(14:1)-2, O
and O
FA B-lipid
18:0) I-lipid
in O
MSA. O

The O
samples O
were O
extracted O
using O
a O
single O
extraction O
with O
400 O
µl O
of O
methanol, O
containing O
the O
recovery O
standards: O
FA B-lipid
13:0, I-lipid
fluorophenylglycine, O
chlorophenylalanine O
and O
d6-cholesterol. O

The O
calibration O
standards O
were O
prepared O
by O
spiking O
with O
20 O
μL O
of O
the O
appropriate O
calibrator O
working O
solution O
into O
700 O
μL O
of O
PMC O
in O
Eppendorf O
tube O
kept O
in O
ice, O
resulting O
in O
the O
calibration O
concentrations O
of O
0.02, O
0.05, O
0.1, O
0.2, O
0.5, O
1, O
2, O
5, O
10, O
20, O
50, O
100 O
ng/mL O
for O
all O
analytes O
except O
0.2, O
0.5, O
1, O
2, O
5, O
10, O
20, O
50, O
100, O
200, O
500, O
and O
1000 O
ng/mL O
for O
FA B-lipid
18:2;OH I-lipid
and O
9-HOTrE O
in O
the O
final O
solution. O

Cer B-lipid
22:0;O2 I-lipid

As O
expected, O
the O
ketone O
body O
FA B-lipid
4:0;3OH I-lipid
was O
inversely O
correlated O
to O
glucose, O
insulin O
and O
HOMA O
in O
several O
of O
the O
analyses. O

Among O
the O
20 O
healthy O
adults, O
18 O
(90%) O
had O
ZS O
scores O
below O
the O
optimal O
cutoff O
of O
−0.1634, O
15 O
(75%) O
had O
PE B-lipid
18:2 I-lipid
scores O
below O
the O
cutoff O
of O
1447.81, O
14 O
(70%) O
had O
GNOE O
scores O
lower O
than O
the O
cutoff O
of O
227.56, O
and O
17 O
(85%) O
had O
MG B-lipid
18:2 I-lipid
scores O
less O
than O
the O
cutoff O
of O
237.9. O

However, O
the O
relative O
amounts O
of O
LPC B-lipid
16:0 I-lipid
and O
LPC B-lipid
20:4 I-lipid
were O
also O
slightly O
decreased O
in O
the O
PC/BTC/CRC/OVC O
groups O
compared O
with O
those O
in O
the O
control O
group O
(Fig. O
). O

Lower O
muscle O
lipids O
in O
OIR O
versus O
Lean O
included O
GM3 B-lipid
18:1;O2/22:0, I-lipid
LPC B-lipid
22:6, I-lipid
LPE B-lipid
22:6, I-lipid
and O
DG B-lipid
18:2_18:2. I-lipid

5-, O
12- O
and O
FA B-lipid
20:4;15OH I-lipid
(5-HETE, O
FA B-lipid
20:4;OH, I-lipid
15-HETE), O
prostaglandin O
E_2 O
, O
D_2 O
and O
F_2 O
(PGE_2 O
, O
PGD_2 O
, O
PGF_2 O
), O
lipoxin O
A_4 O
and O
B_4 O
(LXA_4 O
, O
LXB_4 O
), O
leukotriene O
B_4 O
(LTB_4 O
), O
thromboxane O
B_2 O
(TXB_2 O
), O
arachidonic O
acid O
(AA), O
FA B-lipid
22:6 I-lipid
(DHA), O
eicosapentanoic O
acid O
(EPA), O
resolvin O
D1 O
(RvD1), O
and O
neuroprotectin O
D1 O
(NPD1). O

As O
shown O
in O
, O
levels O
of O
Cer B-lipid
22:0;O2 I-lipid
and O
Cer B-lipid
24:0;O2 I-lipid
concentrations O
were O
significantly O
elevated O
in O
type O
2 O
diabetics O
compared O
to O
controls. O

When O
the O
spectrum O
for O
12-oxo O
FA B-lipid
20:4(6,8,10,14);(OH)2 I-lipid
and O
one O
of O
these O
unknowns O
was O
compared, O
it O
was O
observed O
that O
their O
patterns O
were O
highly O
similar O
thus O
indicating O
a O
common O
chemical O
structure O
(–). O

On O
the O
contrary, O
high O
LPC B-lipid
16:0 I-lipid
levels O
were O
reported O
to O
be O
an O
ovarian O
cancer O
biomarker. O

LPC B-lipid
22:6 I-lipid
as O
a O
blood O
biomarker O
of O
large-artery O
atherosclerosis O
(LAA) O
([C] O
cohort O
1; O
[D] O
cohort O
2). O

shows O
data O
acquired O
from O
the O
2 : 1 O
mixture O
of O
PC B-lipid
16:0/18:1 I-lipid
and O
PC B-lipid
18:1/16:0 I-lipid
(total O
concentration O
kept O
at O
10 O
μM). O

Figure  O
shows O
a O
representative O
MS/MS O
spectra O
of O
PE B-lipid
P-18:0/20:4(5Z,8Z,11Z,14Z) I-lipid
an O
ether-linked O
phosphatidylethanolamine O
(PE), O
in O
one O
of O
our O
samples, O
that O
was O
identified O
in O
negative O
mode, O
and O
a O
previously O
published O
spectra O
of O
the O
same O
ion O
confirming O
our O
tentative O
identification O
of O
that O
ion. O

ATP O
adenosine O
triphosphate, O
Fatty O
acids O
capric O
acid, O
cis-9-palmitoleic O
acid, O
FA B-lipid
12:0, I-lipid
oleic O
acid, O
palmitic O
acid O
or O
stearic O
acid, O
MDD O
major O
depressive O
disorder, O
PUFAs O
FA B-lipid
20:5 I-lipid
(EPA, O
ω-3) O
and O
arachidonic O
acid O
(AA, O
ω-6), O
SAM O
S-adenosylmethionine, O

The O
branching O
ratio O
is O
the O
ratio O
of O
peak O
areas O
of O
two O
mass O
transitions O
of O
Cer B-lipid
22:0;O2 I-lipid
(m/z O
622 O
to O
264 O
/ O
m/z O
622 O
to O
280) O
or O
Cer B-lipid
24:0;O2 I-lipid
(m/z O
650 O
to O
264 O
/ O
m/z O
650 O
to O
280), O
used O
to O
assure O
specificity O
of O
the O
detection. O

Phospholipids O
for O
relative O
quantification O
were O
extracted O
as O
neutral O
lipids O
but O
with O
2% O
acetic O
acid O
in O
the O
presence O
of O
the O
internals O
standards O
(Cer O
18:1;O2/15:0 I-lipid
16 ng; O
PE B-lipid
12:0/12:0 I-lipid
180 ng; O
PC B-lipid
13:0/13:0 I-lipid

As O
a O
result, O
FA B-lipid
9:0 I-lipid
(C9) O
and O
p-hydroxybenzoic O
acid O
displayed O
relatively O
high O
sensitivity, O
with O
values O
of O
86.7% O
and O
90%, O
respectively. O

FA B-lipid
20:4(6,8,10,14);(OH)2 I-lipid
was O
found O
to O
be O
significant O
owing O
to O
its O
apparent O
complete O
depletion O
in O
serum O
of O
CLL O
patients. O

Although O
little O
is O
known O
regarding O
the O
action O
of O
FA B-lipid
9:0 I-lipid
in O
humans, O
FA O
9:0 O
is O
a O
family O
of O
medium-chain O
fatty O
acids O
including O
valproic O
acid, O
which O
is O
used O
to O
treat O
manic O
symptoms O
in O
patients O
with O
bipolar O
disorder O
and O
schizophrenia. O

LPC B-lipid
18:2 I-lipid
level O
was O
positively O
correlated O
with O
TG O
level. O

For O
the O
Bligh-Dyer O
method, O
the O
1:10, O
1:20, O
and O
1:100 O
(v/v) O
sample-to-solvent O
ratios O
provided O
higher O
peak O
areas O
for O
Cer B-lipid
18:1;O2/24:0, I-lipid
all O
LPCs, O
and O
many O
PC/PE/PG O
lipid O
classes O
compared O
to O
the O
1:4 O
(v/v) O
sample-to-solvent O
ratio. O

The O
significant O
alterations O
in O
the O
levels O
of O
FA B-lipid
10:0 I-lipid
in O
the O
PCa O
cells O
study O
is O
in O
concordance O
with O
previously O
reported O
in O
serum O
of O
PCa O
patients. O

Only O
a O
few O
correlations O
were O
found O
for O
PC B-lipid
28:1, I-lipid
PC B-lipid
30:2, I-lipid
PC B-lipid
40:1, I-lipid
PC B-lipid
42:6, I-lipid
GPCe O
38:6 O
and O
SM B-lipid
22:3;O2 I-lipid
within O
the O
respective O
lipid O
classes. O

According O
to O
univariate O
statistics, O
the O
following O
compounds O
were O
significantly O
different O
between O
samples O
from O
the O
pre-symptomatic O
individuals O
and O
controls: O
oleic O
acid O
(p O
= O
0.040, O
AUROC O
= O
0.67), O
β-hydroxypalmitic O
acid O
(p O
= O
0.049, O
AUROC O
= O
0.67), O
kynurenine O
(p O
= O
0.015, O
AUROC O
= O
0.66), O
hypoxanthine O
(p O
= O
0.044, O
AUROC O
= O
0.69), O
LPC B-lipid
16:0 I-lipid
(p O
= O
0.049, O
AUROC O
= O
0.69), O
LPC B-lipid
14:0 I-lipid
(p O
= O
0.012, O
AUROC O
= O
0.70) O
and O
3-indolelactic O
acid O
(p O
= O
0.045, O
AUROC O
= O
0.65). O

presents O
the O
results O
of O
five-fold O
cross-validation O
method O
and O
suggests O
that O
four O
metabolites, O
FA B-lipid
9:0, I-lipid
glucose, O
galactose, O
and O
cysteine O
+ O
cystine, O
demonstrated O
high O
predictivity O
and O
sensitivity O
(AUC, O
0.9–1.0; O
sensitivity, O
>90%). O

The O
15-lipooxygenase O
product O
FA B-lipid
20:4;OH, I-lipid
a O
lipid O
signalling O
eicosanoid O
involved O
in O
inflammation O
and O
endothelial O
cell O
adhesion, O
was O
also O
identified O
as O
a O
potentially O
important O
metabolic O
signature O
of O
HCC, O
possessing O
a O
sensitivity O
of O
83.3 O
and O
a O
specificity O
of O
59.3 O
for O
HCC O
presence O
(AUC O
= O
0.705, O
P O
= O
0.0011). O

Our O
results O
suggest O
that O
in O
subjects O
converting O
to O
AD O
putrescine O
is O
channelled O
towards O
the O
production O
of O
spermidines O
and O
spermines, O
whereas O
in O
stable O
MCI O
putrescine O
has O
other O
fates O
(production O
of O
N-acetylputrescine O
or O
FAL B-lipid
4:0;4NH2). I-lipid

The O
later O
eluting O
isomer O
of O
PC B-lipid
38:4 I-lipid
coeluted O
with O
our O
standard, O
PC B-lipid
18:0/20:4. I-lipid

Thirdly, O
classification O
using O
ROC O
analysis O
identified O
FA B-lipid
15:0, I-lipid
linoleoyl O
carnitine O
and O
1-linoleoylglycerophosphocholine O
as O
the O
top O
discriminating O
metabolites O
in O
determining O
the O
extent O
of O
myocardial O
injury. O

report O
concentrations O
after O
consumption O
of O
JWH-018 O
and O
JWH-073, O
which O
were O
in O
the O
low O
nanogram O
per O
milliliter O
range O
for O
the O
main O
metabolites O
(JWH-018 O
5-hydroxypentyl O
23 O
ng/mL/26 O
ng/mL; O
JWH-018 O
FA B-lipid
5:0 I-lipid
16.5 O
ng/mL/16 O
ng/mL, O
JWH-073 O
FA B-lipid
4:0 I-lipid
6.2 O
ng/mL). O

Beam-type O
CID O
revealed O
that O
it O
contained O
two O
fatty O
acyl O
compositional O
isomers: O
PC B-lipid
16:0_17:1 I-lipid
(major) O
and O
PC B-lipid
15:0_18:1 I-lipid
(minor). O

(d17So1P), O
Cer B-lipid
18:1;O2/17:0 I-lipid
(C17Cer), O
and O
glucosylceramide O
(d18:1/17:0) O
(C17GlcCer) O
were O
purchased O
from O
Avanti O
Polar O
Lipids. O

The O
extraction O
solvent O
was O
spiked O
with O
compounds O
not O
detected O
in O
unspiked O
human O
stool O
samples O
[SM O
18:1;O2/16:0, I-lipid
PE B-lipid
17:0/17:0, I-lipid
PC B-lipid
19:0/19:0, I-lipid
TG B-lipid
13:0/13:0/13:0, I-lipid
Cer B-lipid
18:1;O2/17:0 I-lipid
and O
ChoE(12:0)]. O

However, O
PC B-lipid
32:0, I-lipid
and O
PC B-lipid
38:4 I-lipid
decreased O
in O
MF O
tissue O
compared O
to O
adjacent O
non-tumor O
tissue. O

We O
further, O
additionally, O
demonstrated O
that O
the O
mechanism O
of O
signaling O
of O
FA B-lipid
20:4;OH I-lipid
in O
regulation O
of O
cell O
growth O
is O
via O
activation O
of O
the O
small-GTPase O
Ras O
in O
HRPTEC O
cells. O

Lipid O
molecules O
contributing O
to O
the O
highest O
variation O
on O
the O
MDS O
plot O
generated O
by O
RF O
analysis O
were O
identified O
as O
PCs O
(32:2, O
32:3, O
36:5, O
42:6), O
ePC O
(32:2), O
DG B-lipid
36:4, I-lipid
and O
TG B-lipid
58:7. I-lipid

Specifically, O
S1P O
and O
LPA B-lipid
18:2(9Z,12Z)/0:0 I-lipid
each O
had O
a O
good O
predictability O
of O
disease O
status O
(AUC O
> O
0.80; O
). O

In O
vivo O
, O
FA B-lipid
20:4(6,8,10,14);(OH)2 I-lipid
is O
rapidly O
metabolized O
by O
different O
pathways O
in O
an O
attempt O
to O
decrease O
the O
inflammatory O
effects O
caused O
by O
this O
mediator. O

DG B-lipid
16:0_18:1 I-lipid
is O
likely O
the O
most O
abundant O
product O
of O
glucose O
stimulated O
triacylglycerol O
hydrolysis O
(Pearson O
et O
al. O
), O
in O
our O
study O
this O
specie O
was O
associated O
with O
a O
decrease O
in O
C-peptide O
after O
6 months, O
indicating O
a O
potential O
link O
between O
glucose O
levels O
at O
1 month O
and O
a O
significant O
higher O
decrease O
in O
c-peptide O
over O
time. O

Discriminatory O
metabolites O
were O
significantly O
identified O
as O
palmitic O
acid, O
stearic O
acid, O
oleic O
acid, O
benzoic O
acid, O
FA B-lipid
4:0, I-lipid
cholesterol, O
glycine, O
3-heptanone, O
4-heptanone, O
FAL B-lipid
6:0, I-lipid
1-tetradecanol O
and O
naphthalene O
. O

SR-A O
levels O
were O
inversely O
related O
to O
levels O
of O
the O
PUFA, O
FA B-lipid
22:5 I-lipid
(DPA) O
(22:5). O

LPC B-lipid
18:1 I-lipid
in O
HCC O
plasma O
showed O
a O
statistically O
significant O
(P<0.05) O
lower O
plasma O
concentration O
than O
in O
HV O
plasma O
was O
determined O
in O
this O
quantitative O
assay O
and O
also O
a O
statistically O
significant O
(P<0.05) O
downregulation O
in O
HCC O
relative O
to O
LC. O

Fourteen O
organic O
acids O
were O
found, O
with O
50% O
of O
them O
being O
decreased O
(i.e., O
2-(4-(2-acetoxyethyl)-2,5-dimethoxyphenyl)acetic O
acid O
(methyl O
ester), O
ethyl O
(R)-(−)-3-hydroxy-2-methyl-propionate, O
3-methyl-oxirane-2-carboxylic O
acid O
(methyl O
ester), O
itaconic O
acid, O
malonic O
acid, O
FA B-lipid
3:0;3OH, I-lipid
and O
trimethyl O
2-methoxypropane-1,2,3-tricarboxylate) O
and O
50% O
of O
them O
being O
increased O
(i.e., O
4-HPA, O
2-hydroxybutyric O
acid, O
carbamic O
acid, O
dimethyl O
ethylidenemalonate, O
lactic O
acid, O
benzoic O
acid, O
3,5-bis(1,1-dimethylethyl)-4-hydroxy-(methyl O
ester), O
and O
para O
-toluic O
acid). O

Subjects O
with O
RVD O
exhibited O
increased O
plasma O
FA B-lipid
20:4;OHs, I-lipid
reduced O
excretion O
of O
FA O
20:4;OH, O
decreased O
plasma O
EETs, O
and O
increased O
plasma O
DHETs. O

(A) O
Scores O
plot O
from O
OPLS O
multivariate O
analysis, O
cross-validated O
score O
plot O
resulting O
from O
OPLS O
modeling O
of O
Total O
Blood O
ST B-lipid
27:1;O. I-lipid

Cer B-lipid
18:0;1OH,3OH/24:0 I-lipid
shares O
the O
same O
sphingosine O
backbone O
and O
fatty O
acyl O
side O
chains O
as O
SM(1) B-lipid
18:0;3OH/24:0 I-lipid
such O
that O
the O
two O
are O
inter-convertible O
via O
the O
enzymatic O
actions O
of O
sphingomyelin O
synthase O
(SMS; O
Cer→SM) O
and O
sphingomyelinase O
(SMase; O
SM→Cer). O

Although O
most O
patients O
with O
FESZ O
received O
medication O
and O
should O
be O
carefully O
considered, O
two O
independent O
sample O
sets O
were O
analyzed O
and O
increased O
levels O
of O
creatine, O
and O
decreased O
levels O
of O
betaine, O
FA B-lipid
9:0, I-lipid
benzoic O
acid O
and O
perillic O
acid O
were O
identified O
in O
patients O
with O
FESZ. O

Plasma O
samples O
were O
analyzed O
from O
participants O
in O
the O
ST B-lipid
27:1;O I-lipid
and O
Pharmacogenetics O
(CAP) O
study—a O
trial O
in O
which O
944 O
Caucasian O
and O
African-American O
men O
and O
women O
with O
total O
cholesterol O
levels O
of O
160–400 O
mg/dL O
were O
treated O
with O
simvastatin O
40 O
mg/d O
for O
6 O
weeks. O

FA B-lipid
20:4;OOH, I-lipid
FA O
20:4;OOH, O
9-HpODE, O
FA B-lipid
18:2;OOH, I-lipid
and O
PGF_3α O
need O
to O
be O
noted O
(Electronic O
Supplementary O
Material O
Table O
S-3). O

As O
a O
result, O
seven O
“differential O
metabolites” O
were O
identified, O
including: O
PC B-lipid
40:4 I-lipid
(1), O
2-hexenoylcarnitine O
(2), O
beta-D-glucopyranuronic O
acid O
(3), O
DG B-lipid
38:9 I-lipid
(4), O
MG B-lipid
20:3 I-lipid
(5), O
LPC B-lipid
18:2 I-lipid
(6) O
and O
LPC B-lipid
16:0 I-lipid
(7). O

, O
PC B-lipid
40:2 I-lipid
is O
lower O
in O
NRP O
compared O
with O
RP O
before O
and O
during O
treatment, O
probably O
resulting O
from O
dysregulation O
of O
choline O
metabolism, O
a O
known O
metabolic O
hallmark O
associated O
with O
oncogenesis O
and O
cancer O
progression. O

The O
ions O
552.3 O
and O
526.3 O
resulted O
from O
loss O
of O
the O
sn-1 O
acyl O
group O
as O
a O
lithium O
salt O
from O
PC B-lipid
18:1/22:5 I-lipid
and O
PC B-lipid
20:2/20:4, I-lipid
respectively. O

One O
feature O
(M327T82 O
in O
Table ) O
was O
identified O
as O
FA B-lipid
22:6 I-lipid
(Metlin O
ID: O
3457, O
HMDB0002183) O
with O
a O
METLIN O
score O
of O
58 O
and O
a O
HMDB O
fit O
of O
85%. O

We O
selected O
four O
metabolites O
as O
the O
potential O
predictive O
biomarkers O
for O
survival, O
based O
on O
CC<0.5 O
between O
each O
selected O
metabolite, O
which O
were O
Kynurenine, O
Acetylcarnitine, O
PC B-lipid
42:11, I-lipid
and O
LPE B-lipid
22:0/0:0 I-lipid
(Table O
). O

In O
variance O
analysis, O
the O
3 O
selected O
serum O
metabolites O
(FA O
6:2(2,4), I-lipid
4-methylphenyl O
dodecanoate O
and O
glycerol O
tributanoate) O
in O
ESI_+ O
mode O
in O
both O
high O
level O
group O
and O
low O
level O
group O
could O
definitely O
distinguish O
GC O
patients O
from O
healthy O
peoples O
(Figure O
) O
(p O
<0.05). O

When O
counting O
Δ9/Δ11 O
relative O
isomer O
ratios O
for O
PE B-lipid
16:0_18:1, I-lipid
the O
RSDs O
(8%) O
of O
the O
technique O
repeats O
are O
quite O
comparable O
to O
that O
of O
subclass O
quantitation; O
however, O
individual-to-individual O
variation O
is O
significantly O
reduced, O
at O
10% O
for O
normal O
control O
(I O
_Δ9 O
/I O
_Δ11 O
 = 5.0 ± 0.5) O
and O
11% O
for O
T2D O
(I O
_Δ9 O
/I O
_Δ11 O
 = 3.8 ± 0.4). O

Abbreviations: O
CoA, O
coenzyme O
A; O
DHA, O
FA B-lipid
22:6; I-lipid
EPA, O
FA B-lipid
20:5. I-lipid

We O
also O
used O
Mass O
Hunter O
Quantitative O
Analysis O
B.07.00 O
to O
quantify O
the O
FA B-lipid
20:4;OH I-lipid
in O
which O
the O
deuterated O
internal O
standard O
FA O
20:4;OH-d8 O
(Cayman O
Chemical) O
was O
used. O

The O
most O
altered O
metabolite O
was O
Cer B-lipid
42:3;O2, I-lipid
and O
all O
metabolites O
were O
higher O
in O
the O
case O
group, O
except O
for O
two O
of O
them, O
Cer B-lipid
18:1;O2/16:0 I-lipid
and O
TG B-lipid
54:1, I-lipid
which O
were O
lower O
than O
the O
control O
group O
(A). O

The O
matrix O
factors[] O
for O
Cer B-lipid
22:0;O2 I-lipid
and O
Cer B-lipid
24:0;O2 I-lipid
were O
assessed O
by O
comparing O
the O
peak O
response O
of O
the O
([_2 O
H_4 O
]Cer O
22:0;O2 O
and O
[_2 O
H_4 O
]Cer O
24:0;O2) O
from O
post-extraction O
spiked O
samples O
to O
equivalent O
pure O
compound O
solutions O
in O
isopropanol-chloroform O
(9:1). O

Levels O
of O
LPC B-lipid
16:0 I-lipid
were O
decreased O
in O
MSA O
and O
PSP. O

ROC O
curves O
for O
the O
combination O
of O
2-methoxy-4-methylphenol, O
3-aminosalicylic O
acid, O
3-hydroxyanthranilic O
acid O
and O
FA B-lipid
5:0;4OH. I-lipid

The O
possible O
protective O
role O
of O
omega-3 O
fatty O
acids O
on O
type O
2 O
diabetes O
in O
Asians, O
particularly O
Chinese, O
was O
partly O
supported O
by O
our O
findings O
that O
increased O
omega-3 O
fatty O
acids, O
such O
as O
α O
-linolenic O
acid, O
FA B-lipid
20:5, I-lipid
and O
FA B-lipid
22:6, I-lipid
were O
observed O
only O
in O
prevalent O
type O
2 O
diabetes, O
which O
might O
elevate O
anti-inflammatory O
effects O
for O
self-stress O
protection. O

The O
mass O
spectra O
and O
the O
possible O
fragment O
structures O
were O
then O
performed O
to O
confirm O
the O
chemical O
structures O
of O
the O
LPG B-lipid
20:5, I-lipid
which O
were O
shown O
in O
and O
Based O
on O
the O
Youden O
index O
J O
= O
max O
(sensitivity O
+specificity-1), O
a O
cut-off O
value O
of O
LysoPG O
(20:5) O
was O
selected. O

Notably, O
decreased O
plasma O
concentrations O
of O
LPC B-lipid
18:1 I-lipid
and O
LPC B-lipid
18:2 I-lipid
have O
been O
detected O
in O
both O
subjects O
with O
metabolically O
unhealthy O
obesity O
and O
metabolically O
healthy O
obesity. O

By O
UPLC-MS, O
we O
identified O
2 O
metabolites O
(with O
an O
LoA O
≤ O
3) O
that O
were O
higher O
in O
PRP O
compared O
with O
PFP O
samples: O
PE B-lipid
18:0/18:2 I-lipid
and O
PC B-lipid
P-16:0/20:4. I-lipid

ABCD2 O
+ O
LAA O
+ O
LPC B-lipid
20:4 I-lipid
= O
0.711, O
p O
< O
0.001; O
integrated O
discrimination O
improvement O
(IDI) O
test O
for O
comparison O
of O
prediction O
models: O
p O
< O
0.0001). O

We O
found O
that O
the O
level O
of O
PG B-lipid
12:0/13:0 I-lipid
was O
highest O
in O
the O
BT O
group, O
followed O
by O
PP O
and O
GP. O

Oral O
high O
fat O
supplementation-induced O
upregulation O
of O
LysoPC O
metabolites, O
including O
LPC B-lipid
16:0, I-lipid
might O
have O
yielded O
beneficial O
health O
effects O
in O
postoperative O
pancreatic O
cancer O
patients. O

S14b_† O
), O
PC B-lipid
15:0_18:1, I-lipid
PC B-lipid
16:0_17:1, I-lipid
and O
PC B-lipid
16:0_17:0. I-lipid

The O
serum O
levels O
of O
FA B-lipid
12:0, I-lipid
pinitol, O
maltol, O
sucrose, O
and O
S13 O
were O
significantly O
higher O
after O
soy O
drink O
intake O
than O
after O
milk O
and O
cheese O
intake O
at O
1, O
2, O
and O
4 O
h O
(see O
Tables O
S3 O
and O
S4). O

The O
transitions O
monitored O
were: O
337.2>207.1 O
and O
337.2>319.3 O
for O
14(15)-DiHET O
(rt: O
5.4 O
min), O
337.2>167.0 O
and O
337.2>319.3 O
for O
11(12)-DiHET O
(rt: O
5.7 O
min), O
319.2>275.3, O
319.2>301.3 O
and O
319.2>289.2 O
for O
FA B-lipid
20:4;OH I-lipid
(rt: O
6.6 O
min), O
319.2>219.2, O
319.2>301.3 O
and O
319.2>175.0 O
for O
FA O
20:4;OH O
(rt: O
7.6 O
min), O
319.2>179.2, O
319.2>301.3 O
and O
319.2>257.2 O
for O
FA O
20:4;OH O
(rt: O
8.2 O
min), O
303.2>259.2, O
303.2>205.1 O
and O
303.2>58.7 O
for O
AA O
(rt: O
15.1 O
min) O
and O
311.3>267.3 O
for O
AA-d8 O
(rt: O
14.9 O
min). O

In O
a O
second O
example O
from O
human O
plasma O
extract, O
the O
elution O
profile O
of O
a O
phosphatidylcholine O
of O
sum O
composition O
PC B-lipid
32:2 I-lipid
is O
shown O
in O
. O

However, O
only O
TG B-lipid
49:1 I-lipid
and O
TG B-lipid
51:1 I-lipid
were O
identified O
as O
putative O
biomarkers O
when O
the O
lipidome O
was O
compared O
between O
meloxicam- O
and O
saline-treated O
cats O
and O
within O
the O
meloxicam O
group O
(post-treatment O
vs O
baseline O
lipidome) O

It O
was O
therefore O
decided O
to O
profile O
the O
HCC O
and O
control O
plasmas O
for O
LPA B-lipid
16:0, I-lipid
a O
product O
of O
LPD/autotaxin. O

In O
the O
differential O
diagnosis O
of O
cirrhosis O
and O
early O
stage O
HCC, O
the O
AUCs O
of O
LysoPC O
[18:2 O
(9Z,12Z)], O
LysoPC O
(FA O
P-16:0), I-lipid
asparaginyl-proline O
and O
vaccenic O
acid O
were O
increased O
compared O
with O
that O
of O
AFP. O

In O
the O
present O
study, O
the O
concentrations O
of O
3 O
VOCs O
(4-heptanone, O
2-methylpyrazine O
and O
FAL B-lipid
4:0;2Me) I-lipid
were O
significantly O
different O
between O
the O
B-NHL O
group O
and O
healthy O
control O
group. O

This O
is O
especially O
evident O
for O
FAL B-lipid
16:1(2);OH I-lipid
(ESM O
Fig. O
S6). O

(B) O
Formal O
Concept O
Analysis O
to O
visualize O
sorting O
of O
samples O
based O
on O
the O
relative O
abundance O
of O
PC B-lipid
39:6 I-lipid
and O
FC O
(22:3) O
in O
PCa O
(red O
squares) O
compared O
to O
control O
(black O
squares). O

What’s O
more, O
some O
studies O
have O
reported O
that O
changed O
concentrations O
of O
lysoPCs O
are O
associated O
with O
the O
risk O
of O
T2DM, O
especially O
LPC B-lipid
18:2, I-lipid
which O
was O
significantly O
altered O
in O
patients O
with O
impaired O
glucose O
tolerance O
(IGT) O
and O
was O
identified O
as O
an O
IGT-specific O
biomarker. O

Significant O
metabolites O
according O
to O
the O
jack-knife O
confidence O
intervals O
were: O
oleic O
acid O
(lower O
levels O
in O
pre-symptomatic O
individuals O
compared O
with O
controls), O
as O
well O
as O
kynurenine O
and O
LPC B-lipid
16:0 I-lipid
(higher O
levels O
in O
pre-symptomatic O
individuals O
in O
comparison O
to O
controls). O

ST B-lipid
27:1;O I-lipid
is O
metabolized O
via O
different O
processes O
into O
2 O
major O
primary O
bile O
acids O
(CDCA O
and O
CA). O

2-HBA, O
FA B-lipid
4:0;2OH; I-lipid
αKGDH, O
α-ketoglutarate O
dehydrogenase; O
Cu, O
copper; O
GSH, O
glutathione; O
PDH, O
pyruvate O
dehydrogenase; O
ROS, O
reactive O
oxygen O
species; O
SAH, O
S-adenosylhomocysteine; O
SAHH, O
S-adenosylhomocysteine O
hydrolase; O
SAM, O
S-adenosylmethionine O
We O
observed O
significant O
changes O
in O
metabolites O
related O
to O
the O
TCA O
cycle O
in O
patients O
with O
WD O
compared O
to O
healthy O
subjects. O

Based O
on O
this O
pattern, O
a O
higher O
LPC B-lipid
16:1 I-lipid
level O
was O
detected O
in O
the O
obese O
group, O
while O
higher O
levels O
of O
other O
LPC O
species O
were O
observed O
in O
nonobese O
subjects. O

However, O
there O
is O
also O
co-elution O
of O
neutral O
and O
lipid O
compounds; O
testosterone-d_2 O
co-eluted O
with O
17:0 O
Cer, O
and O
PC B-lipid
19:0/15:1 I-lipid
co-eluted O
with O
an O
unknown O
compound O
with O
a O
similar O
m/ O

Eleven O
metabolites O
i.e. O
lactic O
acid O
(CAS O
# O
79-33-4), O
phosphoric O
acid O
(CAS O
# O
7664-38-2), O
benzoic O
acid O
(CAS O
# O
2078-12-8), O
naphthalene O
(CAS O
# O
29422-13-7), O
d-glucose O
(CAS O
# O
128705-73-7), O
altrose O
(CAS O
# O
1990-29-0), O
palmitic O
acid O
(CAS O
# O
64519-82-0), O
FA B-lipid
18:0 I-lipid
(CAS O
# O
1188-75-6), O
stearic O
acid O
(CAS O
# O
57-11-4), O
1-propene O
(CAS O
# O
1000154-23-3) O
and O
cholesterol O
(CAS O
# O
1856-05-9), O
out O
of O
32 O
low O
molecular O
weight O
metabolites O
were O
putatively O
identified O
(level O
2 O
of O
Metabolomics O
Standard O
Initiative O
for O
the O
identification) O
by O
comparing O
the O
mass O
spectra O
of O
the O
peaks O
with O
those O
available O
in O
the O
NIST O
mass O
spectral O
(Wiley O
registry O
NIST O
11) O
and O
Fiehn O
RTL O
libraries O
at O
70% O
similarity O
index, O
while O
the O
remaining O
were O
not O
identified O
at O
this O
similarity O
index. O

Direct O
correlations O
(P O
< O
0.05) O
between O
vitamin O
B-12 O
status, O
nerve O
function, O
or O
both O
were O
identified O
with O
the O
following O
metabolites: O
sophorose, O
sulfuric O
acid, O
sorbitol, O
phosphoric O
acid, O
pelargonic O
acid, O
octadecanol, O
N-methylalanine, O
methionine O
sulfoxide, O
maleimide, O
lysine, O
lauric O
acid, O
isolinoleic O
acid, O
inositol-allo, O
inosine, O
hydroxylamine, O
FA B-lipid
17:0, I-lipid
cyclohexylamine, O
citrulline, O
citric O
acid, O
cholesterol, O
caprylic O
acid, O
capric O
acid, O
benzoic O
acid, O
3,6-anhydrogalactose, O
and O
3-aminoisobutyric O
acid. O

Specifically, O
centenarians O
exhibit O
lower O
concentration O
of O
FA B-lipid
20:3;11OH,12OH I-lipid
(FA O
20:3;(OH)2), I-lipid
FA B-lipid
18:2;9OH I-lipid
(9-HODE), O
and O
FA B-lipid
18:2;9oxo I-lipid
(9-oxo-HODE), O
and O
increased O
concentrations O
of O
FA B-lipid
20:4;15OH I-lipid
(15-HETE), O
and O
leukotriene O
E4 O
(LTE4). O

A O
three O
lipid O
signature O
including O
ePC O
38:5, O
PC B-lipid
40:3 I-lipid
and O
PC B-lipid
42:4 I-lipid
is O
potential O
to O
screen O
patients O
for O
diagnosis O
of O
PCa. O

FA B-lipid
20:4;OH I-lipid
signaling O
in O
HRPTEC O
cells O
through O
activation O
of O
the O
small-GTPase O
Ras. O

In O
addition, O
plasma O
levels O
of O
FA B-lipid
20:4;OH I-lipid
correlated O
positively O
with O
body O
mass O
index O
(r O
= O
0.427, O
p O
= O
0.007) O
and O
diastolic O
blood O
pressure O
(r O
= O
0.365, O
p O
= O
0.028). O

We O
did, O
however, O
measure O
increased O
LPC O
species O
enriched O
for O
SaFAs, O
including O
LPC B-lipid
17:0 I-lipid
and O
LPC B-lipid
20:0, I-lipid
whereas O
the O
proportional O
amount O
of O
LPC B-lipid
18:2 I-lipid
was O
significantly O
decreased. O

12- O
hydroxyeicosatetraenoic O
acid O
(HETE), O
FA B-lipid
22:6 I-lipid
(DHA), O
arachidonic O
acid O
(AA), O
and O
prostaglandin O
(PG) O
derivatives O
were O
detected O
at O
relatively O
high O
levels O
among O
the O
monitored O
ions. O

Combining O
information O
from O
fatty O
acyl O
composition O
(C17:0 O
and O
C22:4), O
this O
PE O
was O
confidently O
identified O
as O
PE B-lipid
17:0_22:4 I-lipid
(Δ7, O
10, O
13, O
and O
16), O
with O
no O
other O
major O
C=C O
location O
isomer O
identified. O

In O
addition, O
FA B-lipid
20:5;OH I-lipid
lessens O
inflammatory O
reaction O
of O
macrophage O
through O
the O
JNK O
pathway O
and O
has O
a O
protection O
effect O
against O
hepatic O
steatosis. O

The O
finding O
that O
patients O
with O
FESZ O
have O
reduced O
concentrations O
of O
FA B-lipid
9:0 I-lipid
suggests O
that O
abnormal O
inositol O
phosphate O
signaling O
may O
have O
a O
role O
in O
schizophrenia. O

Diminished O
EET O
levels O
will O
augment O
FA B-lipid
20:4;OH I-lipid
vasoconstrictor O
activity, O
because O
FA B-lipid
20:3;Ep I-lipid
functions O
as O
a O
physiological O
antagonist O
of O
FA O
20:4;OH. O

Relative O
to O
the O
control, O
the O
major O
sn O
-isomer O
PC B-lipid
16:0/18:1 I-lipid
and O
the O
CC O
location O
isomer O
C18:1(Δ9) O
were O
found O
to O
increase O
significantly O
in O
the O
cancerous O
tissue O
samples O
(P O
= O
3.5 O
× O
10_–7 O
and O
P O
= O
2 O
× O
10_–4 O
, O
respectively, O
). O

Finally, O
a O
potential O
LAA O
biomarker, O
LPC B-lipid
22:6, I-lipid
was O
also O
described. O

We O
observed O
significant O
differences O
between O
patients O
with O
autism O
and O
controls O
in O
overall O
samples O
for O
12 O
of O
17 O
metabolites: O
3 O
in O
the O
positive O
mode O
(decanoylcarnitine, O
phytosphingosine, O
pregnanetriol) O
and O
9 O
in O
the O
negative O
mode O
(DHA, O
DPA, O
adrenic O
acid, O
S1P, O
LPA B-lipid
18:2(9Z,12Z)/0:0, I-lipid
LPE B-lipid
0:0/16:0, I-lipid
LPE B-lipid
18:0/0:0, I-lipid
UA O
and O
9,10-EOA). O

Plasma O
and O
urinary O
levels O
of O
FA B-lipid
20:4;OH I-lipid
were O
significantly O
different O
among O
the O
3 O
groups; O
subjects O
with O
RVD O
demonstrated O
the O
highest O
plasma O
and O
the O
lowest O
urinary O
values O
of O
FA O
20:4;OH. O

For O
the O
duration O
of O
our O
hydrolysis O
studies, O
no O
change O
in O
JWH-018 O
FA B-lipid
5:0 I-lipid
peak O
areas O
was O
observed. O

The O
present O
finding O
of O
elevated O
expression O
of O
CYP4A/F O
enzymes O
in O
human O
cancer O
tissue O
suggests O
that O
FA B-lipid
20:4;OH I-lipid
inhibitors O
and O
antagonists O
may O
be O
useful O
in O
the O
treatment O
of O
cancer. O

Furthermore, O
the O
two O
metabolites O
[LPC O
16:0, I-lipid
LPC B-lipid
20:4] I-lipid
shown O
to O
discriminate O
these O
diseases O
are O
potentially O
useful O
when O
combined O
with O
other, O
previously O
identified O
protein O
or O
metabolic O
biomarkers O
for O
predictive, O
preventive O
and O
personalized O
medical O
approach. O

47 O
target O
metabolites O
(L-Tyrosine, O
L-Phenylalanine, O
L-Threonine, O
L-(+)-Lactic O
acid, O
L-Valine, O
L-Leucine, O
L-Proline, O
Betaine, O
FA B-lipid
16:0, I-lipid
Stearic O
acid, O
Glycine, O
(±)-a-Tocopherol, O
β-Sitoseterol, O
L-Tryptophan, O
DL-glyceraldehyde, O
Glycocholic O
acid, O
oleic O
acid, O
FA B-lipid
20:0, I-lipid
FA B-lipid
6:0, I-lipid
FA B-lipid
7:0, I-lipid
FA B-lipid
9:0, I-lipid
Galactose, O
Sucrose, O
Sorbitol, O
myoinositol, O
Fructose, O
Cellobiose, O
Urea, O
Isoleucine, O
Alanine, O
citric O
acid, O
Azelaic O
acid, O
Aspartic O
acid, O
4-Hydroxybenzoic O
acid, O
Pimelic O
acid, O
L-Serine, O
Hypoxanthine, O
D-Homoserine, O
Uric O
acid, O
Trimethylamine O
oxide, O
FA B-lipid
4:0;COOH, I-lipid
Allantoin, O
FA B-lipid
18:2, I-lipid
Citrulline, O
Oxaloacetic O
acid, O
and O
Sorbose O
andα-ketoglutaric O
acid) O
were O
selected O
from O
previous O
studies O
that O
reported O
new O
biomarkers O
or O
important O
metabolites O
for O
EH O
and O
related O
cardiovascular O
diseases. O

Hepatic O
levels O
of O
(a) O
arachidonic O
acid O
(C20:4n-6), O
eicosapentanoic O
acid O
(C20:5n-3), O
and O
FA B-lipid
22:6 I-lipid
(C22:6n-3) O
in O
the O
patients O
studied O
(upper O
panel) O
and O
mouse O
models O
(lower O
panel). O

Subsequent O
correlation O
analysis O
revealed O
that O
GNOE, O
MG B-lipid
18:2 I-lipid
and O
PE B-lipid
18:2 I-lipid
had O
the O
highest O
correlation O
with O
BAV. O

PC B-lipid
18:1/22:6 I-lipid
is O
annotated O
by O
the O
algorithm O
whereas O
SM B-lipid
18:1;O2/18:2 I-lipid
was O
characterised O
by O
MS/MS O
analysis O
using O
Li O
infusion. O

LPCs O
enriched O
for O
the O
SaFA O
margaric O
acid O
(17:0) O
were O
positively O
associated O
with O
the O
proportion O
of O
patrolling O
monocytes, O
and O
LPC B-lipid
20:0 I-lipid
was O
positively O
associated O
with O
surface O
expression O
of O
SR-A O
on O
patrolling O
monocytes O
and O
CD36 O
on O
inflammatory O
monocytes. O

Notably, O
7 O
of O
the O
RF-selected O
features O
showed O
additional O
significant O
associations O
with O
BMI, O
including O
the O
positively O
related O
PS B-lipid
38:1 I-lipid
at O
m/z O
800.5850 O
(ESI+, O
RT O
= O
5.20 O
min) O
and O
negatively O
associated O
LysoPC O
(18:1) O
at O
m/z O
506.3249 O
(ESI–, O
RT O
= O
1.39 O
min), O
TG B-lipid
62:9 I-lipid
at O
m/z O
967.8174 O
(ESI+, O
RT O
= O
7.97 O
min), O
and O
LysoPC O
(18:2) O
at O
m/z O
504.3093 O
(ESI–, O
RT O
= O
1.12 O
min) O
(Fig. O

Abbreviations: O
Ceramide O
(Cer), O
Monohexosylceramide O
(MHC), O
Dihexosylceramide O
(DHC), O
Trihexosylceramide O
(THC), O
GM3 O
ganglioside O
(GM3), O
Sphingomyelin O
(SM), O
Phosphatidylcholine O
(PC), O
Alkylphosphatidylcholine O
(PC-O), O
Phosphatidylcholine O
plasmalogen O
(PC-P), O
Lysophosphatidylcholine O
(LPC), O
Lysoalkylphosphatidylcholine O
(LPC(O)), O
Phosphatidylethanolamine O
(PE), O
Akylphosphatidylethanolamine O
(PE-O), O
Phosphatidylethanolamine O
plasmalogen O
(PE-P), O
Lysophosphatidylethanolamine O
(LPE), O
Phosphatidylinositol O
(PI), O
Lysophosphatidylinositol O
(LPI), O
Phosphatidylserine O
(PS), O
Free O
ST B-lipid
27:1;O I-lipid
(COH), O
ST O
27:1;O O
Ester O
(Ce), O
Diacylglycerol O
(DG), O
Triacylglycerol O
(TG). O

Kynurenine, O
Acetylcarnitine, O
PC B-lipid
42:11, I-lipid
and O
LPE B-lipid
20:0/0:0 I-lipid
were O
selected O
as O
the O
vital O
survival O
potential O
predictive O
biomarkers. O

, O
Our O
data O
clearly O
suggest O
that O
PC B-lipid
16:0_18:1 I-lipid
may O
contain O
four O
structural O
isomers O
from O
combinations O
of O
two O
sn O
-isomers O
and O
two O
CC O
location O
isomers O
of O
the O
C18:1. O

When O
the O
positive O
ion O
CTS O
data O
was O
filtered O
in O
two O
dimensions O
specifically O
for O
PE O
plasmalogens O
containing O
AA O
(precursors O
of O
m/z O
361.274±10 O
ppm O
and O
precursors O
of O
product O
ions O
with O
a O
CCS O
value O
of O
197±1 O
Å_2 O
), O
the O
resultant O
plot O
is O
simplified O
compared O
to O
only O
filtering O
in O
one O
dimension O
and O
allowed O
for O
the O
identification O
of O
an O
AA O
containing O
lyso O
PE, O
PE(OH/20:4) O
at O
m/z O
502, O
and O
three O
AA O
containing O
plasmalogen O
PE O
lipids, O
PE B-lipid
P-16:0/20:4 I-lipid
at O
m/z O
724, O
PE B-lipid
P-18:0/20:4 I-lipid
at O
m/z O
752, O
and O
PE B-lipid
P-20:0/20:4 I-lipid
at O
m/z O
780 O
from O
the O
positive O
ion O
CTS O
data. O

The O
following O
lysophosphocholines O
(LPC) O
and O
lysophosphatidic O
acids O
(LPA) O
were O
obtained O
from O
Avanti O
Polar O
Lipids O
(Alabaster, O
AL): O
LPC B-lipid
14:0/0:0, I-lipid
LPC B-lipid
15:0/0:0, I-lipid
LPC B-lipid
16:0/0:0, I-lipid
LPA B-lipid
16:0/0:0, I-lipid
LPA B-lipid
17:0/0:0, I-lipid
LPC B-lipid
18:0/0:0, I-lipid
and O
LPC B-lipid
18:1/0:0. I-lipid

In O
particular, O
SM B-lipid
18:1;O2/23:1 I-lipid
and O
SM B-lipid
18:1;O2/24:2 I-lipid
were O
elevated O
in O
females, O
which O
has O
previously O
been O
reported O
[, O
] O
and O
could O
potentially O
be O
accounted O
for O
by O
differences O
in O
LDL-C O
cholesterol O
levels. O

800 O
μl O
of O
methanol, O
100 O
μl O
of O
distilled O
water O
and O
10 O
μl O
of O
“FA O
17:0 I-lipid
in O
methanol” O
(1 O
mg O
FA O
17:0 O
in O
1 O
ml O
methanol) O
were O
added O
and O
mixed. O

These O
would O
have O
had O
a O
severe O
adverse O
impact O
on O
the O
identification O
of O
C=C O
locations O
in O
PE B-lipid
39:4 I-lipid
if O
PB–MS/MS O
analysis O
was O
directly O
applied O
to O
the O
lipid O
extract. O

As O
mentioned O
above, O
this O
interpretation O
is O
supported O
by O
the O
work O
of O
Yin O
et O
al O
., O
whereby O
HCC O
and O
HBV-induced O
LC O
shared O
a O
common O
decline O
in O
four O
LPCs, O
three O
of O
which O
(LPC O
18:0, I-lipid
(18:2) O
and O
(18:3)) O
are O
reported O
in O
this O
study. O

Multivariate O
COX O
regression O
analysis O
showed O
TNM O
staging O
(p O
<0.005, O
95% O
confidence O
interval O
(95% O
CI) O
1.002-1.034), O
FA B-lipid
6:2(2,4) I-lipid
(p O
<0.005, O
95% O
CI O
1.002-1.027), O
4-methylphenyl O
dodecanoate O
(p O
<0.005, O
95% O
95% O
CI O
1.002-1.001) O
and O
glycerol O
tributanoate O
(p O
<0.005, O
95% O
CI O
1.002-1.032) O
were O
independent O
prognostic O
factors O
of O
GC O
(Table O
). O

ST B-lipid
27:1;O I-lipid
concentrations O
in O
CSF O
were O
not O
changed O
except O
for O
patients O
diagnosed O
with O
amyotrophic O
lateral O
sclerosis O
(P O
 < 0.01) O
or O
pathogen-based O
infections O
of O
the O
CNS O
(P O
 < 0.05) O
where O
they O
were O
elevated. O

Lactobacilli O
produce O
lactic O
acid O
and O
acetic O
acid O
from O
glucose O
and O
fructose O
by O
a O
fermentation O
process O
, O
while O
Veillonella O
transform O
lactic O
acid O
into O
acetic O
acid O
and O
FA B-lipid
3:0 I-lipid
. O

Significant O
changes O
in O
FA B-lipid
20:5 I-lipid
(EPA) O
or O
FA B-lipid
22:6 I-lipid
(DHA) O
(P O
value = 0.59 O
and O
0.65, O
respectively) O
in O
serum O
following O
RYGB O
were O
not O
observed. O

Combining O
all O
the O
above O
information, O
it O
is O
evident O
that O
PC B-lipid
16:0_18:1 I-lipid
contains O
four O
distinct O
molecular O
species, O
including O
two O
sn O
-isomers O
and O
two O
CC O
location O
isomers O
of O
the O
C18:1. O

The O
other O
product O
ion O
in O
the O
spectrum O
appeared O
at O
m/z O
279 O
provides O
the O
information O
about O
one O
of O
the O
acyl O
moiety O
of O
the O
PE O
as O
FA B-lipid
18:3. I-lipid

Non-esterified O
diols O
and O
alcohols O
of O
C18-PUFA O
LA O
and O
ALA O
in O
cluster O
1, O
represented O
by O
FA B-lipid
18:2;OH, I-lipid
were O
enriched O
to O
a O
greater O
extent O
postprandially O
in O
pro-atherogenic O
TGRL. O

Moreover, O
Lv O
et O
al. O
demonstrated O
circulating O
levels O
of O
PC B-lipid
40:1 I-lipid
and O
PC B-lipid
40:4 I-lipid
as O
upregulated O
lipid O
molecular O
species O
that O
are O
specific O
for O
small O
cell O
lung O
cancer O
(SCLC). O

As O
FA B-lipid
20:4;OH I-lipid
functions O
in O
these O
segments O
to O
inhibit O
Na_+ O
reabsorption, O
a O
deficiency O
will O
promote O
Na_+ O
reabsorption O
and O
elevate O
blood O
pressure O
as O
occurs O
in O
the O
Dahl O
salt-sensitive O
rat. O

The O
most O
commonly O
observed O
esters O
were O
the O
methyl O
esters O
of O
FA B-lipid
3:0, I-lipid
FA B-lipid
4:0, I-lipid
FA B-lipid
5:0 I-lipid
and O
FA B-lipid
6:0. I-lipid

In O
addition O
the O
ratio O
of O
the O
direct O
precursors O
of O
pro-resolution O
lipid O
mediators O
(14-HDHA, O
17-HDHA O
and O
18-HEPE), O
which O
are O
precursors O
of O
resolvins O
and O
protectins, O
was O
calculated O
against O
various O
precursors O
of O
the O
AA-derived O
and O
mainly O
pro-inflammatory O
derivatives O
(5-HETE, O
FA B-lipid
20:4;OH I-lipid
and O
15-HETE) O
as O
well O
as O
ratios O
of O
sum O
of O
HEPEs O
and O
sum O
of O
HDHAs O
vs. O
the O
sum O
of O
HETEs O
were O
calculated. O

18:2, O
[M-H]-; O
(E) O
lysoPE O
18:1, O
[M-H]-; O
(F) O
LPE B-lipid
22:5, I-lipid
[M-H]- O

(A) O
Insulin; O
(B) O
Glucose; O
(C) O
Alanine O
transaminase O
(ALT); O
(D) O
Aspartate O
transaminase O
(AST); O
(E) O
Triacylglycerides O
(TAG); O
(F) O
ST B-lipid
27:1;O; I-lipid
(D) O
Low-density O
lipoprotein O
cholesterol O
(LDL-C); O
(H) O
High-density O
lipoprotein O
cholesterol O
(HDL-C). O

Note O
that O
FAL B-lipid
10:1(2);OH, I-lipid
FAL B-lipid
8:1(2) I-lipid
and O
2-decenal O
do O
not O
pass O
the O
correlation O
cutoff O
and O
hence O
are O
shown O
at O
the O
bottom-left O
side. O

ST B-lipid
27:1;O I-lipid
eluted O
in O
fraction O
3 O
from O
the O
first O
SPE O
column O
(SPE1-Fr-3) O
and, O
in O
its O
GP-tagged O
form, O
in O
fractions O
1 O
and O
2 O
from O
the O
second O
column O
(SPE2-Fr-1 O
and O
SPE2-Fr-2). O

Similar O
to O
SM B-lipid
16:0;O2 I-lipid
and O
SM B-lipid
22:0;O2, I-lipid
PC B-lipid
34:2, I-lipid
PC B-lipid
34:1, I-lipid
PC B-lipid
36:4, I-lipid
and O
PC B-lipid
36:2 I-lipid
were O
identified O
in O
the O
extracts O
of O
protocols O
(i)–(iv), O
not O
in O
the O
extracts O
derived O
from O
protocols O
(v) O
and O
(vi). O

The O
present O
study O
aimed O
to O
determine O
the O
profile O
of O
omega-3 O
or O
n3- O
as O
well O
as O
omega-6 O
or O
n6- O
polyunsaturated O
fatty O
acids O
(PUFAs) O
and O
PUFA-metabolites O
of O
linoleic O
acid, O
arachidonic O
acid O
(AA), O
FA B-lipid
20:5 I-lipid
(EPA) O
and O
FA B-lipid
22:6 I-lipid
(DHA) O
in O
gingival O
crevicular O
fluid O
(GCF), O
saliva O
and O
serum O
in O
AgP O
patients O
and O
healthy O
controls. O

All O
monoacyl O
lipids O
except O
cholesterol O
esters, O
such O
as O
monoacylglycerols O
and O
monoacylglycerophospholipids, O
were O
normalized O
with O
LPC B-lipid
17:0/0:0, I-lipid
all O
diacyl O
lipids O
except O
ethanolamine O
phospholipids O
were O
normalized O
with O
PC B-lipid
17:0/17:0, I-lipid
all O
ceramides O
with O
Cer B-lipid
18:1;O2/17:0, I-lipid
all O
diacyl O
ethanolamine O
phospholipids O
with O
PE B-lipid
17:0/17:0, I-lipid
and O
TG O
and O
cholesterol O
esters O
with O
TG B-lipid
17:0/17:0/17:0. I-lipid

This O
decrease O
may O
be O
due O
to O
instability O
of O
FA B-lipid
20:3;Ep I-lipid
in O
acidic O
and O
neutral O
conditions O
[, O
]. O

Although O
changes O
in O
the O
abundance O
of O
2 O
compounds O
(Propanoic O
acid, O
2-(methoxyimino)-, O
trimethylsilyl O
ester O
and O
FA B-lipid
9:0, I-lipid
trimethylsilyl O
ester O
) O
were O
statistically O
significant O
(unadjusted O
p O
-values O
≤0.05) O
in O
a O
paired-sample O
comparison O
of O
patients O
before O
and O
after O
treatment, O
they O
failed O
to O
meet O
the O
established O
criterion O
of O
FDR. O

In O
another O
study, O
it O
was O
revealed O
that O
while O
intracellular O
concentrations O
of O
FA B-lipid
20:4(6,8,10,14);(OH)2 I-lipid
can O
be O
higher O
in O
B-CLL O
cells O
relative O
to O
their O
normal O
counterpart, O
plasma O
concentrations O
of O
FA O
20:4(6,8,10,14);(OH)2 O
may O
not O
be O
statistically O
different O
between O
patients O
and O
controls, O
the O
reason O
being O
that O
FA O
20:4(6,8,10,14);(OH)2 O
can O
be O
metabolised O
into O
20-OH-FA O
20:4(6,8,10,14);(OH)2 O
that O
is O
a O
non-circulating O
metabolite. O

Lipid O
standards O
were O
purchased O
from O
Avanti O
Polar O
Lipids O
(Alabaster, O
AL), O
which O
include O
Cer B-lipid
18:0;O2/24:1, I-lipid
PC B-lipid
18:0/18:1, I-lipid
PE B-lipid
16:0/18:1, I-lipid
PG B-lipid
16:0/18:1, I-lipid
PS B-lipid
16:0/18:1, I-lipid
PI B-lipid
21:0/22:6, I-lipid
PC B-lipid
P-18:0/20:4, I-lipid
PC B-lipid
O-18:0/20:0, I-lipid
PE B-lipid
P-18:0/22:6, I-lipid
PE B-lipid
O-18:0/18:0, I-lipid
SM B-lipid
18:1;O2/12:0, I-lipid
and O
d5-TG O
ISTD O
Mix O
I. O

Metabolites O
that O
contributed O
in O
both O
analyses O
were O
FA B-lipid
4:0;3OH,4OH, I-lipid
FA B-lipid
22:5, I-lipid
and O
uric O
acid. O

FAL B-lipid
6:0 I-lipid
is O
a O
breakdown O
product O
of O
lipid O
peroxidation O
that O
is O
formed O
as O
a O
result O
of O
oxygen O
free O
radical O
activity. O

A O
prominent O
TG O
that O
was O
identified O
from O
the O
study O
was O
TG B-lipid
56:4 I-lipid
with O
the O
suggestion O
that O
this O
species O
may O
serve O
as O
a O
potential O
biomarker O
for O
the O
detection O
of O
acquired O
obesity. O

In O
the O
whole O
set O
(the O
combined O
training O
and O
validation O
sets), O
the O
most O
significant O
difference O
in O
mean O
plasma O
concentration O
was O
PC B-lipid
38:3 I-lipid
(p O
=1.00749E-17, O
Student's O
t-test). O

Alterations O
in O
levels O
of O
CYP O
enzymes, O
FA B-lipid
20:4;OH I-lipid
or O
EETs O
contribute O
to O
endothelial O
dysfunction O
and O
cardiovascular O
diseases O
such O
as O
ischemic O
injury, O
hypertension O
and O
atherosclerosis O
[,]. O

Moreover, O
LPC B-lipid
20:4 I-lipid
also O
arose O
as O
a O
potential O
SR O
biomarker, O
increasing O
the O
prediction O
power O
of O
age, O
blood O
pressure, O
clinical O
features, O
duration O
of O
symptoms, O
and O
diabetes O
scale O
(ABCD2) O
and O
LAA. O

At O
pH O
2, O
8 O
VOCs O
stood O
out, O
namely, O
cyclohexanone O
(Fig. O
), O
4-methylheptan-2-one, O
2-methylpentane-1,3-diol, O
4-methylbenzaldehyde O
(Fig. O
), O
1-(3,5-dimethylfuran-2-yl) O
ethanone, O
methyl O
benzoate, O
FA B-lipid
9:0 I-lipid
and O
FA B-lipid
10:0 I-lipid
(Fig. O
) O
as O
they O
revealed O
to O
be O
important O
for O
the O
separation O
between O
all O
PCa O
cell O
lines O
and O
normal O
cell O
line O
(Table O
). O

Additional O
CID O
spectra O
performed O
in O
the O
negative O
ionization O
mode O
enabled O
to O
determine O
the O
presence O
of O
the O
fatty O
acids O
FA O
16:1 O
(m/z O
253.2172) O
(b) O
and O
FA B-lipid
16:0 I-lipid
(m/z O
255.2327) O
(c), O
corresponding O
to O
two O
distinct O
PC O
species, O
namely O
alkyl–acyl-PC O
32e:1 O
and O
alkenyl–acyl-PC32p:0 O

Higher O
levels O
of O
the O
12-LOX O
products O
FA B-lipid
20:4;OH I-lipid
and O
14-HDHA O
in O
serum O
are O
likely O
due O
to O
activation O
of O
platelet-derived O
12-LOX O
during O
the O
clotting O
cascade. O

For O
PS, O
PS B-lipid
40:1 I-lipid
and O
PS B-lipid
42:8 I-lipid
were O
detected O
only O
in O
the O
extracts O
from O
protocols O
(iii)–(vi). O

Particularly, O
decreased O
LPG B-lipid
20:5 I-lipid
level O
was O
identified O
as O
the O
most O
important O
prognostic O
feature O
in O
our O
model, O
which O
may O
provide O
additional O
prognostic O
information O
for O
EOC. O

Twenty-one O
of O
the O
67 O
metabolites O
between O
healthy O
and O
hepatic O
were O
unique, O
including O
FA B-lipid
4:0;2OH, I-lipid
2-ketoisocaproic O
acid, O
α-ketoglutarate, O
glycerol-alpha-phosphate, O
oxamic O
acid, O
urea, O
and O
uridine. O

[FA O
24:1(15) I-lipid
or O
24:1, O
n O
-9 O
by O
the O
International O
Union O
of O
Pure O
and O
Applied O
Chemistry O
nomenclature] O
is O
a O
long O
chain O
of O
monounsaturated O
omega-9 O
fatty O
acids O
that O
are O
particularly O
abundant O
in O
the O
white O
matter O
of O
the O
brain. O

Forty-nine O
out O
of O
the O
of O
50 O
analytes O
showed O
recoveries O
in O
the O
range O
of O
66.8 O
to O
121.2% O
except O
FA B-lipid
20:3;Ep I-lipid
that O
showed O
recoveries O
of O
38.3–66.2% O
across O
three O
QC O
concentration O
levels O
(QC3 O
to O
QC5) O
in O
PMC O
and O
plasma. O

The O
levels O
of O
FA B-lipid
18:2;13OH, I-lipid
which O
is O
a O
lipoxygenation O
product O
derived O
from O
linoleic O
acid O
(C18:2), O
was O
also O
significantly O
lower O
in O
the O
LC O
group. O

 O
Authentic O
standards O
PC B-lipid
18:0/18:2, I-lipid
PC(cis O
18:1/cis O
18:1), O
PC(trans O
18:1/trans O
18:1), O
PC O
18:0/18:2, O
PC B-lipid
18:0/20:4, I-lipid
and O
PC B-lipid
18:0/22:6 I-lipid
were O
analysed O
by O
LC-MS O
with O
sample O
analysis O
instrumental O
conditions. O

The O
data O
show O
that O
in O
some O
cases O
multiple O
lipid O
species O
are O
present O
in O
a O
single O
nominal O
mass O
peak O
(e.g., O
m/z O
750, O
[PE O
FA B-lipid
P-36:2 I-lipid
+ O
Na]_+ O
), O
while O
other O
peaks O
are O
principally O
due O
to O
a O
single O
lipid O
species O
(e.g., O
m/z O
754, O
[PC O
32:1 O
+ O
Na]_+ O
). O

Lysophosphatidylcholines O
(LysoPCs) O
including O
LPC B-lipid
18:2, I-lipid
LPC B-lipid
20:3 I-lipid
and O
LPC B-lipid
22:5 I-lipid
were O
obviously O
decreased O
in O
plasma O
from O
HAPE O
subjects O
relative O
to O
healthy O
controls, O
suggesting O
the O
phospholipid O
metabolism O
is O
implicated O
in O
stroke O
patients. O

ROC O
curves O
for O
dUMP, O
L-octaoylcarnitine, O
L-proline, O
LysoPC O
(20:1), O
LPS B-lipid
22:0/0:0, I-lipid
and O
uric O
acid. O

The O
precursors O
of O
octenedioic O
acid O
are O
FA B-lipid
9:0;COOH I-lipid
and O
doFA O
9:0;COOH. O

All O
of O
the O
11 O
metabolites O
except O
4 O
(3-hydroxybutyrate, O
N-acetyl-glycine, O
FA B-lipid
4:0;2Me;3OH I-lipid
and O
nonanedioic O
acid) O
have O
been O
identified O
as O
breast O
cancer O
associated O
in O
previous O
studies O
(-). O

By O
contrast, O
inverse O
correlations O
(P O
< O
0.05) O
were O
found O
between O
vitamin O
B-12 O
status O
and O
peripheral O
nerve O
function O
with O
uric O
acid, O
trans-4-hydroxyproline, O
sucrose, O
succinic O
acid, O
pyruvic O
acid, O
phenylalanine, O
oxalic O
acid, O
methionine, O
mannitol, O
maltose, O
malic O
acid, O
indole-3-lactate, O
indole-3-acetate, O
glycerol-α-phosphate, O
cysteine, O
citramalic O
acid, O
asparagine, O
arachidonic O
acid, O
2-ketoisocaproic O
acid, O
and O
FA B-lipid
4:0;2OH. I-lipid

Apo, O
apolipoprotein; O
CI, O
confidence O
interval; O
DHA, O
FA B-lipid
22:6; I-lipid
FA, O
fatty O
acid; O
HOMA‐IR, O
homeostatic O
model O
assessment O
of O
insulin O
resistance; O
IDL, O
intermediate‐density O
lipoprotein; O
LDL, O
low‐density O
lipoprotein; O
MUFA, O
monounsaturated O
fatty O
acid; O
PUFA, O
polyunsaturated O
fatty O
acid; O
SFA, O
saturated O
fatty O
acid. O

Interestingly, O
no O
LTB_4 O
was O
detected O
in O
plasma O
while O
FA B-lipid
20:4;OH I-lipid
was O
one O
of O
the O
metabolites O
increased O
after O
surgery. O

The O
analysis O
distinguished O
between O
patients O
with O
or O
without O
carotid O
atheroma O
plaque O
with O
an O
accuracy O
of O
60% O
and O
revealed O
plasma O
FA B-lipid
20:4;OH I-lipid
as O
the O
primary O
differentiator O
in O
a O
list O
of O
metabolites O
ranked O
in O
order O
of O
importance O
in O
the O
classification O
scheme. O

Through O
inactivation O
or O
immediate O
metabolism O
to O
20-OH-FA O
20:4(6,8,10,14);(OH)2, I-lipid
this O
could O
explain O
the O
absence O
of O
FA O
20:4(6,8,10,14);(OH)2 O
in O
the O
serum O
samples O
from O
patients O
studied O
in O
our O
investigation. O

In O
the O
training O
set, O
the O
most O
significant O
difference O
in O
mean O
plasma O
concentration O
was O
PC B-lipid
38:3 I-lipid
(p O
= O
2.50297E-08, O
Student's O
t-test). O

Significant O
changes O
were O
still O
observed O
for O
these O
lipid O
isomers, O
except O
for O
PC B-lipid
19:0_18:1 I-lipid
(corrected O
value O
of O
−0.0005). O

Specifically, O
FA B-lipid
18:1;(OH)2, I-lipid
14,15-dihydroxy O
eicosatrienoic O
acid O
(FA O
20:3;(OH)2), I-lipid
and O
FA B-lipid
22:5;(OH)2 I-lipid
contributed O
maximally O
to O
the O
discrimination O
of O
pro- O
and O
anti-atherogenic O
subjects O
in O
the O
analysis O
(Fig. ). O

For O
example, O
2-ethoxy-2-methylbutane O
acid, O
FA B-lipid
6:0, I-lipid
phenylmethanol, O
2,4-dimethylheptan-1-ol, O
benzoic O
acid, O
and O
6-pentyloxan-2-one O
were O
significantly O
decreased O
in O
the O
extracellular O
medium O
of O
high O
metastatic O
potential O
cell O
line O
(PC3), O
whereas O
1-ethoxypentane O
was O
significantly O
decreased O
specifically O
in O
moderate O
and O
low O
metastatic O
potential O
cell O
line O
(DU145 O
and O
LNCaP, O
respectively). O

Standards O
of O
racemic O
MG B-lipid
17:0/0:0/0:0, I-lipid
racemic O
DG B-lipid
17:0/17:0/0:0, I-lipid
TG B-lipid
17:0/17:0/17:0, I-lipid
PC(16:1/0:0-D3), O
PC(16:1/16:1-D6), O
and O
TG(16:0/16:0/16:0-13C3) O
were O
purchased O
from O
Larodan O
Fine O
Chemicals O
AB O
(Malmö, O
Sweden). O

As O
previous O
studies O
have O
shown O
that O
lipid O
ratios O
can O
be O
predictive O
of O
certain O
diseases, O
we O
noted O
that O
when O
the O
raw O
intensity O
value O
of O
PS B-lipid
18:0_20:4 I-lipid
was O
divided O
by O
the O
sum O
of O
the O
raw O
intensity O
values O
of O
these O
three O
PS O
lipids, O
all O
fatal O
outcomes O
had O
a O
value O
of O
less O
than O
28.5 O
(average O
value O
of O
21) O
( O
and O
SI O
Appendix O
, O
Fig. O

Alternatively, O
there O
was O
an O
elevation O
in O
the O
levels O
of O
Butyric O
acid, O
α-Tocopherol, O
L-Lysine O
and O
FA B-lipid
3:0, I-lipid
and O
reduction O
in O
the O
levels O
of O
Testosterone O
and O
Ethanol O
in O
saliva O
following O
ART O
administration. O

ST B-lipid
27:1;O I-lipid
(1), O
7-dehydrocholesterol O
(7DHC) O
(3), O
ergosterol O
(7) O
and O
its O
biosynthetic O
precursor O
ergosta-5,7-dienol O
(10) O
are O
the O
most O
abundant O
sterols O
dominating O
lipid O
extracts O
of O
the O
non-inhibited O
N O
. O

Increased O
synthesis O
of O
FA B-lipid
20:4;OH I-lipid
by O
preglomerular O
microvessels O
elevates O
renovascular O
resistance, O
reducing O
intravascular O
pressures O
in O
the O
medullary O
circulation, O
promoting O
movement O
of O
fluid O
into O
the O
vasa O
rectae O
with O
expansion O
of O
extracellular O
fluid O
volume O
and O
elevation O
of O
blood O
pressure. O

MS/MS O
fragmentation O
of O
the O
pseudomolcular O
ion O
of O
PC B-lipid
40:7 I-lipid

In O
this O
study O
we O
observed O
an O
increase O
in O
only O
a O
single, O
minor O
SM O
having O
two O
C18 O
chains O
with O
one O
and O
two O
double O
bonds, O
respectively, O
either O
SM B-lipid
18:2;O2/18:1 I-lipid
or O
SM B-lipid
18:1;O2/18:2. I-lipid

The O
white O
bar O
corresponds O
to O
the O
lipids O
identified O
in O
both O
fractionated O
and O
non-fractionated O
full O
extract, O
but O
the O
level O
of O
identification O
was O
improved O
in O
the O
fractionated O
yeast O
(molecular O
species O
level, O
e.g., O
PC B-lipid
16:0_16:1 I-lipid
instead O
of O
lipid O
species O
level, O
e.g., O
PC B-lipid
32:1). I-lipid

All O
internal O
standards O
were O
obtained O
from O
Avanti O
Polar O
Lipids O
(Alabaster, O
AL, O
USA) O
with O
the O
exception O
of O
FA B-lipid
11:0 I-lipid
and O
trilaurin O
(Sigma O
Aldrich). O

The O
abbreviations O
listed O
here O
refer O
to O
the O
lipid O
classes O
and O
subclasses, O
the O
number O
of O
carbons O
and O
double O
bonds O
will O
be O
listed O
when O
referring O
to O
individual O
lipid O
species, O
such O
as O
LPC B-lipid
22:6 I-lipid
which O
defines O
a O
lysophosphatidylcholine O
containing O
a O
fatty O
acid O
comprising O
22 O
carbon O
atoms O
and O
six O
double O
bonds. O

The O
relationship O
observed O
in O
univariate O
analysis O
between O
insulin O
and O
glycine O
(negative O
correlation), O
glutamic O
acid O
(positive O
correlation) O
and O
FA B-lipid
4:0;3OH I-lipid
(negative O
correlation) O
was O
also O
observed O
in O
the O
multivariate O
analysis. O

This O
class O
ionize O
highly O
efficiently O
in O
positive O
mode O
but O
the O
corresponding O
MS2 O
spectra O
by O
higher-energy O
collisional O
dissociation O
(HCD) O
only O
delivers O
head O
group-specific O
fragments O
that O
cannot O
help O
to O
identify O
the O
fatty O
acyl O
chain O
composition O
(compare O
lipid O
species O
level O
(e.g., O
PC B-lipid
32:1) I-lipid
and O
molecular O
species O
level O
(e.g., O
PC O
16:0_16:1)). O

Results O
are O
reported O
in O
Panels O
B-D. O
In O
particular, O
we O
selected O
phosphatidylcholines O
PCs O
(PC O
34:1, O
PC B-lipid
36:2 I-lipid
and O
PC B-lipid
40:4) I-lipid
in O
Panel O
B, O
C0, O
ACs O
(C2, O
C3) O
in O
Panel O
C O
and O
AAs O
(Leu/Ile/Pro, O
Phe, O
Tyr, O
Glu, O
Met, O
Lys/Gln) O
in O
Panel O
D O
for O
the O
results O
to O
be O
retained O
in O
the O
first O
section O
(α) O
of O
the O
paper O
strip. O

Another O
study, O
comprising O
of O
30,252 O
breast O
cancer O
patients, O
revealed O
that O
FA B-lipid
20:5 I-lipid
and O
FA B-lipid
22:6 I-lipid
were O
significantly O
inversely O
associated O
with O
risk O
for O
breast O
cancer O
(HR: O
0.70, O
95% O
CI: O
0.54–0.90; O
HR: O
0.67, O
95% O
CI: O
0.52–0.87). O

After O
dissolution O
of O
300 O
mg O
of O
the O
purified O
fat O
in O
n-hexane O
(containing O
FA B-lipid
9:0 I-lipid
as O
internal O
standard), O
the O
glycerides O
were O
trans-esterified O
and O
the O
free O
fatty O
acids O
were O
esterified O
to O
the O
corresponding O
methyl O
esters O
by O
a O
solution O
of O
potassium O
hydroxide O
in O
methanol. O

Previous O
study O
reported O
the O
up-regulation O
of O
bile O
acid O
of O
GCDCA O
(or O
GDCA), O
GCA, O
TCA, O
CDCA O
and O
down-regulation O
of O
LPC B-lipid
18:0, I-lipid
LPC B-lipid
18:1, I-lipid
LPC B-lipid
16:0 I-lipid
in O
serum O
of O
patients O
with O
hepatitis O
B O
versus O
healthy O
controls. O

FA B-lipid
18:2 I-lipid
gradually O
degraded O
under O
250 O
°C O
heating, O
and O
∼50% O
disappeared O
after O
heating O
for O
60 O
s O
(Figure O
S3). O

In O
contrast, O
we O
found O
that O
a O
very O
specific O
molecular O
species O
of O
phospholipid, O
PC B-lipid
18:1/22:6, I-lipid
containing O
the O
essential O
omega O
3 O
fatty O
acid O
docosahexaenoic O
acid O
(DHA, O
C22:6) O
and O
oleic O
acid O
(C18:1) O
was O
increased. O

The O
underlying O
fatty O
acid O
signals O
were O
quantified O
by O
the O
peak O
intensities O
of O
the O
diacyl O
fragment O
ions O
normalized O
against O
the O
diacyl O
fragment O
ion O
signal O
of O
the O
pre-extraction O
spiked O
synthetic O
TG B-lipid
17:0/17:0/17:0 I-lipid
standard O
and O
plasma O
volume. O

According O
with O
us, O
recent O
study O
also O
showed O
that O
FA B-lipid
20:4;OH I-lipid
was O
associated O
with O
endothelial O
cell O
proinflammatory O
actions O
that O
promote O
atherosclerosis O
and O
vascular O
remodeling. O

Representative O
mass O
spectrometry O
images O
of O
4 O
MF O
tissue O
samples O
(1, O
3 O
4 O
and O
5; O
left O
to O
right) O
showing O
ions O
SM B-lipid
16:0;O2 I-lipid
at O
m/z O
725.5568, O
PC B-lipid
32:0 I-lipid
at O
m/z O
772.5253, O
PC B-lipid
38:4 I-lipid
at O
m/z O
848.5566, O
PC B-lipid
34:2 I-lipid
at O
m/z O
796.5253, O
PC B-lipid
34:1 I-lipid
at O
m/z O
798.5410, O
PC B-lipid
36:3 I-lipid
at O
m/z O
822.5410, O
and O
PC B-lipid
36:2 I-lipid
at O
m/z O
824.5566. O

They O
also O
found O
changes O
in O
some O
SM O
species, O
such O
as O
an O
increase O
in O
SM B-lipid
16:0;O2 I-lipid
and O
a O
decrease O
in O
SM B-lipid
20:0;O2 I-lipid
concentration. O

Our O
study O
also O
found O
significant O
differential O
expression O
of O
phospholipid O
metabolites O
by O
untargeted O
metabolomic O
study, O
such O
as O
LPC B-lipid
20:4 I-lipid
and O
LPC B-lipid
20:1, I-lipid
and O
CerP B-lipid
18:1;O2/12:0 I-lipid
and O
PE B-lipid
20:4/18:1. I-lipid

The O
list O
of O
detected O
but O
not O
previously O
quantified O
by O
NMR O
compounds O
includes: O
FA B-lipid
5:0;3Me;2OH, I-lipid
2-methyl-3-ketovaleric O
acid, O
2-methylerythritol, O
glucuronic O
acid, O
monomethyl O
glutaric O
acid, O
N-methylhydantoin, O
phosphorylcholine O
and O
scyllitol. O

Moreover, O
levels O
of O
hydrocortisone, O
glutamic O
acid, O
tryptophan, O
FA B-lipid
20:5, I-lipid
FA B-lipid
18:2;13OH, I-lipid
lysophosphatidylcholines, O
and O
lysophosphatidylethanolamines O
were O
associated O
with O
more O
severe O
disease O
(non-relapse-free O
or O
increase O
in O
EDSS). O

Nine O
phosphatidylcholines O
(PCs) O
were O
associated O
with O
obesity O
– O
all O
showing O
inverse O
associations, O
with O
the O
exception O
of O
PC B-lipid
38:3, I-lipid
which O
showed O
a O
positive O
association O
with O
obesity O
(β = 0.36, O
P O
 = 1.7E-06; O
). O

Low O
(DG O
32:0, O
TG B-lipid
48:0), I-lipid
medium O
(DG O
34:2, O
TG B-lipid
52:2), I-lipid
and O
high O
(DG O
36:3, O
TG B-lipid
54:4) I-lipid
abundant O
species O
showed O
a O
good O
correlation O
of O
expected O
and O
measured O
concentrations O
(ESM O
Fig. O

Based O
on O
the O
volcano O
plot, O
we O
selected O
the O
following O
metabolites O
with O
fold O
induction O
above O
±1.5 O
and O
P O
< O
0.05 O
as O
biomarker O
candidates: O
oxalate, O
sarcosine, O
3-hydroxyisovaleric O
acid, O
benzoic O
acid, O
β-alanine, O
creatinine, O
threo-β-hydroxyaspartic O
acid, O
phthalic O
acid, O
5-dehydroquinic O
acid, O
glucose, O
sebacic O
acid, O
galactose, O
galactosamine, O
glucarate, O
urea, O
FA B-lipid
9:0, I-lipid
hypoxanthine, O
and O
cysteine O
+ O
cystine. O

Interestingly, O
plasma O
SM O
levels O
(SM O
36:1, O
SM B-lipid
38:1;O2, I-lipid
and O
SM B-lipid
40:1;O2), I-lipid
which O
are O
related O
with O
fatty O
liver O
and O
insulin O
resistance O
as O
well O
as O
obesity, O
were O
significantly O
elevated O
in O
pre-diabetic O
individuals O
with O
AO O
when O
compared O
to O
normal O
individuals O
with O
AO O
or O
pre-diabetic O
without O
AO O
( O
and O
). O

6d, O
JWH-210 O
5-hydroxyindole; O
6e, O
JWH-210 O
FA B-lipid
5:0; I-lipid
7a, O
JWH-250; O
7b, O
JWH-250 O
5-hydroxypentyl; O
7c, O
JWH-250 O
4-hydroxypentyl; O
7d, O
JWH-250 O
5-hydroxyindole; O
7e, O
JWH-250 O
FA O
5:0; O
8a, O
RCS-4; O
8b, O
RCS-4 O
5-hydroxypentyl; O
8c, O
RCS-4 O
FA O
5:0; O
9a, O
AM2201; O
9b, O
AM2201 O
4-hydroxypentyl; O
9c, O
AM2201 O
6-ydroxyindole; O
10a, O
MAM2201. O

(A) O
Phosphatidic O
acid, O
(B) O
Inosine, O
(C) O
5-hydroxyindoleacetic O
acid, O
(D) O
SE B-lipid
27:1/18:0, I-lipid
(E) O
Uric O
acid. O

While O
no O
significant O
change O
was O
observed O
at O
60 O
and O
100 O
°C O
during O
three O
heating O
periods, O
most O
of O
glutamate O
and O
LPC B-lipid
16:0/0:0 I-lipid
were O
absent O
after O
heating O
at O
250 O
°C O
for O
300 O
s. O
Glutamate O
seems O
to O
be O
among O
the O
most O
labile O
compounds. O

The O
same O
11 O
markers O
were O
top O
ranked O
by O
logistic O
regression, O
with O
the O
exception O
of O
FA B-lipid
8:0;COOH, I-lipid
which O
was O
ranked O
13_th O
overall. O

Abbreviations: O
MSA: O
multiple O
system O
atrophy; O
PSP: O
progressive O
supranuclear O
palsy; O
AUC: O
area O
under O
the O
curve; O
FA: O
fatty O
acid; O
LPC B-lipid
16:0: I-lipid
lysophosphatidylcholine O
(16:0); O
DHEAS: O
dehydroisoandrosterone O
3-sulfate; O
SDMA: O
symmetric O
dimethylarginine O
fatty O
acid; O
AC: O
acylcarnitine; O
Met: O
methionine. O

Among O
these O
13 O
metabolites, O
median O
levels O
of O
serum O
LPC B-lipid
18:2, I-lipid
urocanic O
acid O
and O
indole O
were O
significantly O
lower, O
and O
levels O
of O
L-phenylalanine O
were O
significantly O
higher O
in O
AOSD O
patients O
compared O
with O
HC. O

FAA, O
fatty O
acid O
amide; O
POEA, O
palmitoleoyl O
ethanolamide; O
LPC, O
lysophosphatidylcholine; O
PC, O
phosphatidylcholine; O
PE, O
phosphatidylethanolamine; O
SM, O
sphingomyelin; O
Cer, O
ceramide; O
CE, O
cholesterol O
ester; O
CoQ10, O
coenzyme O
Q10; O
DGLA, O
dihomo-γ-linoleic O
acid; O
AA, O
arachidonic O
acid; O
FA B-lipid
20:3;(OH)2, I-lipid
8,9-dihydroxy-5Z O
,11Z O
,14Z O
-eicosatrienoic O
acid; O
EPA, O
FA B-lipid
20:5 I-lipid
(20:5;5Z O
,8Z O
,11Z O
,14Z O
,17Z O
); O
FA B-lipid
20:5;OH, I-lipid
12-hydroxy-5Z O
,8Z O
,10E,14Z O
,17Z O
-FA O
20:5; O
12-LOX, O
12-lipoxygenase; O
PGE2, O
prostaglandin O
E2; O
PGF2α, O
prostaglandin O
F2α; O
PGF1α, O
prostaglandin O
1α; O
TxB2, O
thromboxane O
B2; O
TxA2, O
thromboxane O
A2; O
mPGES-1, O
microsomal O
prostaglandin O
E O
synthase-1; O
2OG, O
2-oxoglutarate; O
2HG, O
(R O
)-2-hydroxyglutarate; O
DIC, O
disseminated O
intravascular O
coagulation; O
PGH2, O
prostaglandin O
H2 O

To O
test O
this O
hypothesis, O
we O
profiled O
LPA B-lipid
16:0 I-lipid
concentrations O
in O
HCC O
and O
control O
plasma O
by O
UPLC-ESI-TQMS. O

The O
ions O
552.3 O
and O
526.3 O
resulted O
from O
loss O
of O
the O
sn-1 O
acyl O
group O
as O
a O
lithium O
salt O
from O
PC B-lipid
18:1/22:5 I-lipid
and O
PC B-lipid
20:2/20:4, I-lipid
respectively. O

15-lipoxygenation O
products O
were O
quantified O
only O
in O
low O
concentrations O
(≤1 O
nM) O
and O
SPM O
precursor O
FA B-lipid
20:5;OH I-lipid
was O
<LLOQ O
in O
>50% O
of O
the O
samples. O

Logistic O
regression O
demonstrated O
that O
the O
LC O
emergence O
was O
independently O
affected O
by O
serum O
levels O
of O
myristic O
acid, O
palmitic O
acid, O
linoleic O
acid, O
FA B-lipid
20:5 I-lipid
(EPA), O
lysophosphatidic O
acid O
(LPA) O
(18:1), O
glycolic O
acid, O
lysophosphatidylcholine O
(lysoPC) O
(22:6), O
and O
succinylacetone O
(R O
_2 O
= O
0.837, O
P O
< O
0.001). O

No O
differences O
in O
FA B-lipid
3:0 I-lipid
were O
detected O
between O
the O
two O
groups. O

Given O
this, O
good O
quantitation O
of O
FA B-lipid
22:6;OH I-lipid
would O
not O
be O
possible O
if O
there O
was O
not O
enough O
LC O
resolving O
power. O

Particularly, O
two O
of O
the O
three O
candidate O
metabolites O
that O
we O
identified O
as O
having O
the O
best O
predicting O
power, O
PE B-lipid
18:2 I-lipid
and O
glycerophospho-N-ethanolamine, O
belonged O
to O
this O
category. O

In O
this O
study, O
the O
levels O
of O
α-linolenic O
acid O
(C18:3) O
and O
its O
downstream O
ω-3 O
PUFA O
metabolites, O
including O
FA B-lipid
20:5 I-lipid
(C20:5), O
FA B-lipid
22:5 I-lipid
(C22:5), O
and O
FA B-lipid
22:6 I-lipid
(C22:6), O
were O
lower O
in O
the O
LC O
group O
than O
the O
control O
group; O
however, O
FA O
22:5 O
(C22:5) O
and O
FA O
22:6 O
(C22:6) O
did O
not O
show O
significant O
differences. O

1: O
aconitic O
acid; O
2: O
adipic O
acid; O
3: O
alanine; O
5: O
arginine; O
6: O
asparagine; O
7: O
aspartic O
acid; O
9: O
citric O
acid; O
12: O
formic O
acid; O
15: O
glutamic O
acid; O
18: O
glycolic O
acid; O
19: O
hippuric O
acid; O
24: O
isocitric O
acid; O
28: O
lactic O
acid; O
33: O
malonic O
acid; O
39: O
FA B-lipid
3:0; I-lipid
40: O
pyroglutamic O
acid; O
43: O
succinic O
acid; O
45: O
threonine; O
46: O
tryptophan. O

Additionally, O
seven O
lysophosphocholines, O
LPC B-lipid
14:0, I-lipid
LPC B-lipid
16:0, I-lipid
LPC B-lipid
18:1, I-lipid
LPC B-lipid
20:2, I-lipid
LPC B-lipid
20:3, I-lipid
LPC B-lipid
20:4 I-lipid
and O
LPC B-lipid
20:5, I-lipid
were O
downregulated O
in O
HCC O
plasma O
relative O
to O
HV O
plasma. O

The O
levels O
of O
PE B-lipid
16:0/16:1, I-lipid
PE B-lipid
16:0/18:3, I-lipid
PE B-lipid
16:0/18:2, I-lipid
PE B-lipid
18:0/16:0, I-lipid
PE B-lipid
17:0/18:2, I-lipid
PE B-lipid
18:0/17:1, I-lipid
PE B-lipid
17:0/18:1, I-lipid
PE B-lipid
20:5/16:0, I-lipid
PE B-lipid
18:0/18:1, I-lipid
PE B-lipid
18:1/20:4, I-lipid
PE B-lipid
18:0/20:3, I-lipid
PC B-lipid
15:0/18:1, I-lipid
PC B-lipid
16:1/20:5, I-lipid
and O
PC B-lipid
18:0/20:1 I-lipid
in O
early-stage O
NSCLC O
were O
significantly O
increased O
compared O
with O
HC O
(p<0.05). O

We O
believe O
it O
is O
reasonable O
to O
consider O
the O
use O
of O
interventions O
targeting O
the O
metabolism O
of O
LPC B-lipid
P-15:0, I-lipid
PC B-lipid
O-34:5, I-lipid
and O
PC B-lipid
38:6 I-lipid
as O
a O
palliative O
treatment O
for O
patients O
with O
ascites. O

Plasma O
FA B-lipid
20:4;OH I-lipid
significantly O
correlated O
with O
plasma O
renin O
activity O
in O
renovascular O
disease O
(r O
_s O
=0.67; O
n=10; O
P O
<0.05). O

10-HdoHE, O
FA B-lipid
20:5;OH, I-lipid
and O
FA B-lipid
22:6;OH I-lipid
are O
examples O
of O
potentially O
anti-inflammatory O
ω-3 O
fatty O
acids O
[, O
]. O

The O
methanol O
contained O
four O
recovery O
standards O
(DL-2-fluorophenylglycine, O
FA B-lipid
13:0, I-lipid
d6-cholesterol O
and O
4-chlorophenylalanine) O
to O
allow O
confirmation O
of O
extraction O
efficiency. O

For O
instance, O
the O
relative O
isomeric O
ratio O
(I O
_Δ9 O
/I O
_Δ11 O
) O
in O
PE B-lipid
16:0_18:1 I-lipid
decreased O
from O
5.0 ± 0.5 O
in O
control O
to O
3.7 ± 0.3 O
in O
T2D, O
while O
the O
ratio O
of O
PC B-lipid
18:1_20:4 I-lipid
increased O
from O
2.4 ± 0.4 O
in O
control O
to O
4.8 ± 0.9 O
in O
T2D. O
These O
data O
suggest O
that O
the O
metabolic O
processes O
associated O
with O
these O
isomeric O
species O
responded O
quite O
differently O
under O
the O
T2D O
conditions. O

Fourteen O
synthetic O
cannabinoid O
metabolites O
were O
identified, O
including O
JWH-018 O
5-hydroxypentyl, O
JWH-018 O
FA B-lipid
5:0, I-lipid
JWH-018 O
hydroxyindole, O
JWH-073 O
FA B-lipid
4:0, I-lipid
and O
JWH-073 O
4-hydroxybutyl, O
JWH-122 O
5-hydroxypentyl, O
JWH-200 O
6-hydroxyindole, O
JWH-210 O
5-hydroxypentyl, O
and O
JWH-210 O
5-hydroxyindole, O
JWH-250 O
hydroxypentyl, O
JWH-250 O
FA O
5:0, O
JWH-250 O
5-hydroxyindole, O
AM2201 O
4-hydroxypentyl, O
and O
AM O
2201 O
6-hydroxyindole. O

Also, O
alterations O
in O
FA B-lipid
10:0, I-lipid
phenylmethanol O
and O
FA B-lipid
9:0 I-lipid
were O
associated O
with O
melanoma. O

Interestingly, O
PC B-lipid
34:2, I-lipid
PC B-lipid
34:1, I-lipid
PC B-lipid
36:3, I-lipid
and O
PC B-lipid
36:2 I-lipid
increased O
in O
both O
tissues O
and O
sera O
of O
MF O
patients, O
whereas O
SM B-lipid
16:0;O2, I-lipid
PC B-lipid
32:0, I-lipid
and O
PC B-lipid
38:4 I-lipid
levels O
increased O
in O
the O
sera O
but O
decreased O
in O
the O
tissues O
of O
MF O
patients O
compared O
to O
control O
subjects. O

As O
analyzed O
by O
univariate O
analysis O
of O
87 O
serum O
metabolites O
in O
ESI_+ O
mode O
from O
all O
the O
125 O
GC O
patients O
in O
this O
study, O
prognostic O
factors O
for O
GC O
consisted O
of O
FA B-lipid
6:2(2,4), I-lipid
4-methylphenyl O
dodecanoate, O
glycerol O
tributanoate, O
methionyl-methionine O
and O
PG O
(p<0.05 O
) O
(Table O
). O

Serum O
alanine O
aminotransferase O
(ALT), O
aspartate O
aminotransferase O
(AST), O
gamma-glutamyl O
transferase O
(GT), O
glucose, O
cholesterol, O
and O
triglyceride O
concentrations O
were O
measured O
with O
ALT, O
AST, O
GT, O
Glucose, O
ST B-lipid
27:1;O, I-lipid
and O
Triglycerides O
System O
Reagent, O
(Beckman O
Coulter O
Biomedical). O

A O
total O
of O
six O
metabolites O
were O
able O
to O
differentiate O
liver O
cirrhosis O
from O
each O
HCC O
stage O
group, O
namely O
LysoPC O
[18:2 O
(9Z,12Z)], O
LysoPC O
(FA O
P-16:0), I-lipid
asparaginyl-proline, O
vaccenic O
acid, O
L-aspartyl-4-phosphate O
and O
LysoPC O

Interestingly, O
for O
PE B-lipid
18:1_18:1 I-lipid
and O
PC B-lipid
18:1_18:1, I-lipid
we O
also O
detected O
relatively O
low O
intensity O
C=C O
diagnostic O
ions O
that O
could O
be O
assigned O
as O
the O
Δ10 O
isomer, O
although O
other O
unusual O
structural O
isomer O
may O
also O
be O
possible O
(i.e. O
branched O
fatty O
acyl O
(Me-C17:1(Δ9)). O

The O
main O
biological O
functions O
of O
PC B-lipid
15:0/16:0 I-lipid
include O
storing O
energy, O
protecting O
the O
liver, O
increasing O
high-density O
lipoprotein O
levels, O
and O
restoring O
vascular O
elasticity. O

ST B-lipid
27:1;O I-lipid
is O
metabolised O
in O
the O
CNS O
in O
astrocytes O
through O
cytochrome O
P450 O
(CYP) O
27A1 O
catalysed O
oxidation O
to O
(25R)26-HC O
and O
subsequently O
to O
3β-HCA O
and O
then O
on O
to O
3β,7α-diHCA O
and O
7αH,3O-CA O
by O
the O
consecutive O
action O
of O
CYP7B1 O
and O
hydroxysteroid O
dehydrogenase O
(HSD) O
3B7 O
enzymes O
(Fig. O
). O



FA B-lipid
16:0 I-lipid
or O
FA O
16:0 O
is O
one O
of O
the O
most O
common O
saturated O
fatty O
acids O
found O
in O
animals, O
a O
saturated O
fatty O
acid O
found O
in O
fats, O
waxes O
and O
body O
lipids. O

(B) O
Positive O
ionization O
mode O
ion O
images O
of O
m/ O
z O
703.57 O
(SM O
18:1;O2/16:0) I-lipid
in O
red O
and O
m/ O
z O
744.57 O
PC O
(p-16:0/18:1) O
in O
green. O

As O
far O
as O
we O
know, O
no O
previous O
studies O
have O
focused O
on O
the O
role O
of O
LPC B-lipid
22:6 I-lipid
on O
carotid O
plaque O
formation O
or O
stability O
but O
increased O
levels O
in O
symptomatic O
LAA O
patients O
could O
point O
to O
a O
role O
in O
this O
processes. O

Decline O
in O
the O
urinary O
excretion O
of O
FA B-lipid
20:4;OH I-lipid
in O
RVD O
was O
suggested O
to O
reflect O
decreased O
FA O
20:4;OH O
production O
by O
the O
TAL O
and O
proximal O
tubules O
that O
may O
contribute O
to O
increased O
Na_+ O
reabsorption O
in O
these O
tubular O
segments. O

PI O
levels O
generally O
dropped O
over O
the O
course O
of O
infection, O
with O
PI B-lipid
38:4 I-lipid
showing O
the O
largest O
reductions O
from O
basal O
levels O
(approximately O
twofold, O
P O
= O
0.0054 O
at O
96 O
hpi) O
during O
later O
stages O
of O
infection. O

Cer B-lipid
18:1;O2/18:0, I-lipid
its O
precursor O
Cer B-lipid
18:0;1OH,3OH/18:0, I-lipid
and O
Cer B-lipid
18:1;O2/22:0 I-lipid
were O
also O
higher. O

GPCe O
44:4 O
was O
correlated O
only O
with O
GPCe O
38:1, O
and O
GPCe O
30:1 O
was O
correlated O
only O
with O
PC B-lipid
40:2. I-lipid

16 ng; O
PI B-lipid
16:0/17:0 I-lipid
30 ng; O
PS B-lipid
12:0/12:0 I-lipid

ST B-lipid
27:1;O I-lipid
and O
LDL-cholesterol O
also O
showed O
a O
negative O
correlation O
to O
Phe; O
however, O
this O
was O
not O
statistically O
significant. O

PC B-lipid
18:1/22:6 I-lipid
is O
annotated O
by O
the O
algorithm O
whereas O
SM B-lipid
18:1;O2/18:2 I-lipid
was O
characterised O
by O
MS/MS O
analysis O
using O
Li O
infusion. O

On O
the O
other O
hand O
PCs O
containing O
32 O
carbons O
(32:2 O
and O
32:1) O
and O
SM B-lipid
38:3;O2 I-lipid
significantly O
increased O
their O
levels O
during O
radiotherapy O
(cluster O
#3) O
(see O
). O

As O
the O
FA B-lipid
20:4;OH I-lipid
level O
is O
enhanced O
(which O
serves O
as O
marker O
for O
the O
LXA_4 O
pathway), O
we O
cannot O
exclude O
the O
possibility O
that O
LXA_4 O
already O
metabolized O
within O
the O
snap O
shot O
time O
and O
that O
LXA_4 O
levels O
were O
thus O
underestimated. O

At O
1 month O
the O
LPC B-lipid
20:2, I-lipid
LPC B-lipid
22:5 I-lipid
and O
SM B-lipid
32:0;O2 I-lipid
species O
were O
significantly O
negatively O
associated O
to O
C-peptide O
levels O
after O
correction O
for O
multiple O
testing O
and O
at O
1 month, O
cholesteryl O
esters O
were O
associated O
to O
lower O
C-peptide O
levels O
at O
6 months O
(Table ). O

Of O
the O
42 O
metabolites, O
4 O
were O
associated O
with O
changes O
in O
NRI O
scores O
(i), O
which O
were O
N O
-formyl-l-methionine, O
phosphatidylethanolamine O
(PE)(20:4/22:6), O
LPC B-lipid
16:0, I-lipid
and O
SM B-lipid
18:1;O2/24:1. I-lipid

No O
statistically O
significant O
differences O
between O
males O
and O
females, O
neither O
for O
the O
AML O
cases O
nor O
the O
controls, O
were O
found O
for O
the O
following O
plasma O
eicosanoids: O
DHGLA O
[20:3(8Z O
,11Z O
,14Z O
)], O
arachidonic O
acid O
[20:4(5Z O
, O
8Z O
,11Z O
,14Z O
)], O
EPA O
[20:5(5Z O
, O
8Z O
,11Z O
,14Z O
,17Z O
)], O
FA B-lipid
20:3;(OH)2, I-lipid
11-dehydro-TxB2, O
PGE2/8-isoPGE2, O
12-HEPE, O
11β-PGE2, O
15-keto-PGF2α, O
15-keto-PGE2, O
8-iso-15-keto-PGF2α, O
PGF1α, O
and O
PGF2α. O

In O
contrast, O
sn O
-position O
analysis O
revealed O
that O
both O
PC B-lipid
16:0_17:1 I-lipid
and O
PC B-lipid
15:0_18:1 I-lipid
contained O
sn O
-isomers O
and O
each O
pair O
of O
isomers O
showed O
significant O
changes O
between O
cancerous O
and O
normal O
breast O
tissues. O

Correspondingly, O
the O
n3-PUFA-derived O
metabolites, O
17-HDHA O
and O
FA B-lipid
20:5;OH, I-lipid
were O
shown O
to O
be O
formed O
by O
acetylated O
COX-2 O
and O
function O
as O
precursors O
of O
highly O
potent O
specialized O
pro-resolving O
lipid O
mediators. O

FA B-lipid
16:0 I-lipid
(16:0) O
levels O
were O
positively O
associated O
with O
inflammatory O
monocyte O
(CD14_+ O
CD16_+ O
) O
surface O
expression O
of O
the O
innate O
immune O
receptor, O
TLR4, O
and O
myristic O
acid O
(14:0) O
was O
positively O
associated O
with O
levels O
of O
CD36, O
a O
scavenger O
receptor O
involved O
in O
immune O
signaling O
and O
lipid O
uptake. O

(A) O
Total O
Blood O
ST B-lipid
27:1;O. I-lipid

Rauschert O
et O
al. O
reported O
negative O
correlations O
between O
LPC B-lipid
18:1 I-lipid
and O
LPC B-lipid
18:2 I-lipid
with O
waist O
circumference O
that O
were O
independent O
of O
the O
LDL-C O
and O
HDL-C O
levels. O

For O
the O
endogenous O
metabolites, O
similar O
amounts O
of O
oleic O
acid O
(p=0.33), O
linoleic O
acid O
(p=0.49) O
SM(1) B-lipid
18:0;3OH/16:0 I-lipid
(p=0.53) O
and O
PC B-lipid
19:0/15:1 I-lipid
(p=0.38) O
were O
extracted O
using O
either O
method. O

(A) O
PC B-lipid
40:4, I-lipid
Retention O
time O
(RT): O
0.52, O
m/z: O
838.188; O
(B) O
2-Hexenoylcarnitine, O
RT: O
0.56, O
m/z: O
256.8824; O
(C) O
Beta-D-Glucopyranuronic O
acid, O
RT: O
0.80, O
m/z: O
315.0809; O
(D) O
DG B-lipid
38:9, I-lipid
RT: O
3.26, O
m/z: O
635.3920; O
(E) O
MG B-lipid
20:3, I-lipid
RT: O
5.54, O
m/z: O
381.1810; O
(F) O
LPC B-lipid
18:2, I-lipid
RT: O
8.69, O
m/z: O
520.3414; O
(G) O
LPC B-lipid
16:0, I-lipid
RT: O
8.89, O
m/z: O
518.3222. O

Lipid O
extracts O
were O
first O
evaporated O
under O
vacuum O
and O
then O
resuspended O
in O
300 O
µl O
of O
ACN/IPA/H_2 O
O O
(65:30:5 O
v/v/v) O
containing O
PG B-lipid
17:0/17:0 I-lipid
at O
a O
concentration O
of O
5 O
µg/ml. O

This O
would O
result O
from O
Δ7 O
or O
Δ9- O
and O
other O
trans O
-hexadecanoic O
acids O
being O
a O
substrate O
for O
the O
slightly O
promiscuous O
serine O
palmitoyltransferase O
(EC O
2.3.1.50) O
to O
form O
a O
3-ketodehydrosphingosine, O
which O
would O
then O
be O
reduced O
and O
acylated O
by O
oleyl-CoA O
followed O
by O
desaturation O
to O
form O
Cer B-lipid
18:2;O2/18:1. I-lipid

Besides O
the O
high O
levels O
of O
FA B-lipid
20:4;OH I-lipid
and O
FA O
20:4;OH, O
increases O
in O
the O
analogous O
EPA O
metabolites O
FA B-lipid
20:5;OH I-lipid
and O
FA O
20:5;OH O
were O
observed O
(Fig. O

For O
example, O
the O
predicted O
λ O
_b:a O
 O
for O
FAL B-lipid
6:1(2) I-lipid
was O
111, O
therefore O
exchanges O
almost O
exclusively O
in O
the O
airways. O

Characteristic O
MS/MS O
spectra O
of O
m/z O
522.3451 O
in O
a O
biological O
sample O
(C) O
and O
LPC B-lipid
18:1(9Z)/0:0 I-lipid
standard O
(D) O
at O
11.75 min. O

The O
amount O
of O
lipids O
synthesized O
downstream O
Fads1 O
such O
as O
arachidonic O
acid O
(C20:4n-6), O
FA B-lipid
20:5 I-lipid
(C20:5n-3) O
and O
FA B-lipid
22:6 I-lipid
(C22:6n-3) O
were O
dramatically O
decreased O
in O
livers O
of O
mice O
fed O
MCDD. O

Lipid O
standards O
BMP B-lipid
14:0_14:0 I-lipid
and O
PG B-lipid
14:0/14:0 I-lipid
were O
purchased O
from O
Avanti O
Polar O
Lipids, O
Inc., O
and O
analyzed O
using O
the O
same O
LC-MS O
parameters O
as O
the O
plasma O
samples. O

Of O
note, O
SM O
36:0 O
and O
SM(1) B-lipid
18:0;3OH/24:0 I-lipid
were O
also O
associated O
with O
longitudinal O
change O
in O
glucose. O

In O
our O
data, O
lower O
levels O
of O
PC B-lipid
36:4, I-lipid
PE B-lipid
O-36:5, I-lipid
and O
PC B-lipid
O-36:5 I-lipid
and O
in O
the O
CRC O
tissue O
samples O
were O
observed, O
and O
these O
results O
may O
exhibit O
the O
results O
of O
releasing O
FA O
20:4(n-6) O
from O
PC O
36:4 O
and O
PE O
O-36:5 O
and O
the O
results O
of O
releasing O
FA20:5(n-3) O
from O
PC O
O-36:5. O

(C) O
Tandem O
mass O
spectra O
from O
one O
of O
these O
missing O
entries O
(C_22 O
H_34 O
O_3 O
) O
was O
found O
to O
be O
highly O
similar O
to O
the O
tandem O
mass O
spectra O
for O
FA B-lipid
22:6;OH I-lipid
with O
both O
sharing O
common O
fragments O
(blue O
arrows) O
as O
well O
as O
analogous O
fragments O
that O
were O
shifted O
by O
the O
mass O
of O
two O
hydrogens O
(orange O
arrows). O

In O
the O
first O
set, O
step-wise O
discriminant O
analysis O
between O
the O
FESZ O
and O
control O
groups O
showed O
that O
the O
diagnosis O
of O
87.5% O
(28/32) O
of O
the O
subjects O
could O
be O
correctly O
classified O
using O
three O
metabolites O
(betaine, O
glutamate O
and O
FA B-lipid
9:0; I-lipid
Wilks' O
λ O
=0.417, O
P O
<0.001). O

Regardless O
of O
whether O
traditional O
clinical O
plasma O
lipid O
levels O
were O
normal O
or O
abnormal, O
we O
observed O
a O
significant O
reduction O
in O
the O
levels O
of O
five O
lysophosphatidylcholines O
(LPC) O
species O
(LPC O
18:2, I-lipid
LPC B-lipid
18:1, I-lipid
LPC B-lipid
20:2, I-lipid
LPC B-lipid
20:1, I-lipid
and O
LPC B-lipid
20:0) I-lipid
in O
the O
obese O
group O
compared O
with O
the O
normal-weight O
group O
(difference = −31.29% O
to O
−13.19%; O
P O
=9.91 O
× O
10_−5 O
 to 2.28 O
× O
10_−2 O
). O

The O
raw O
LC-MS O
peak O
intensity O
ratio O
of O
PS B-lipid
18:0_20:4 I-lipid
vs. O
3 O
other O
PS O
lipids O
[PS O
18:0_18:1, I-lipid
PS B-lipid
18:0_22:6, I-lipid
PS O
18:0_20:4] O
identified O
per O
donor O
sample. O

The O
three O
metabolites O
(LPC O
16:1, I-lipid
octanoylcarnitine O
and O
decanoylcarnitine) O
that O
significantly O
changed O
only O
in O
ORs O
were O
chosen O
as O
biomarkers O
related O
to O
therapeutic O
effect O
and O
the O
variations O
of O
these O
were O
subjected O
to O
in-depth O
investigation O
over O
the O
treatment O
course. O

These O
values O
would O
be O
expected O
to O
be O
greater O
in O
Sierra O
Leoneans O
as O
their O
daily O
intake O
of O
22:6 O
in O
the O
form O
of O
FA B-lipid
22:6 I-lipid
(DHA) O
is O
greater O
than O
most O
other O
countries, O
summarized O
by O
Forsyth O
et O
al.. O

The O
prohypertensive O
effects O
of O
either O
increased O
or O
decreased O
renal O
FA B-lipid
20:4;OH I-lipid
production O
depends O
on O
the O
principal O
site, O
either O
a O
nephron O
segment O
such O
as O
the O
TAL O
(decreased O
FA O
20:4;OH) O
or O
renal O
microvessels O
(increased O
FA O
20:4;OH) O
as O
the O
afferent O
arteriole, O
that O
exhibits O
altered O
synthesis O
of O
FA O
20:4;OH. O

Similar O
to O
PI, O
PG B-lipid
36:5, I-lipid
PG B-lipid
38:8, I-lipid
PG B-lipid
38:3, I-lipid
PG B-lipid
40:6 I-lipid
and O
PG B-lipid
40:3 I-lipid
were O
detected O
by O
all O
protocols, O
but O
with O
a O
gradual O
increase O
in O
their O
intensities O
from O
protocols O
(i) O
to O
(vi). O

Using O
a O
targeted O
metabolomic O
approach, O
we O
determined O
the O
plasma O
levels O
of O
ATP, O
ADP, O
3’-5’-cyclic-AMP, O
3’-5’-cyclic-GMP, O
AA, O
FA B-lipid
20:4;OH, I-lipid
FA O
20:4;OH, O
FA O
20:4;OH, O
11(12)-DiHETE O
and O
14(15)-DiHETE O
in O
patients O
who O
underwent O
CE O
and O
healthy O
subjects. O

Higher O
concentrations O
(> O
20 O
μM) O
of O
SM B-lipid
34:1;O2, I-lipid
36:1, O
38:1, O
40:1, O
40:2, O
42:2, O
and O
42:3 O
were O
found O
in O
the O
plasma. O

(A) O
Receiver O
operating O
characteristic O
(ROC) O
plot O
obtained O
by O
combining O
three O
metabolites O
namely O
FA B-lipid
15:0, I-lipid
linoleoyl O
carnitine O
and O
1-linoleoylglycerophosphocholine. O

The O
levels O
of O
the O
14 O
discriminative O
LMIs O
were O
higher O
in O
the O
PC O
and O
BTC O
groups O
than O
in O
the O
control, O
CRC O
and O
OVC O
groups, O
but O
only O
two O
LMIs O
discriminated O
between O
PC O
and O
BTC: O
lysophosphatidylcholine O
(LysoPC) O
(16:0) O
and O
LPC B-lipid
20:4. I-lipid

FA B-lipid
20:4;OH I-lipid
and O
leukotriene O
B_4 O
are O
metabolites O
associated O
with O
arachidonic O
acid O
(C20:4) O
metabolism. O

Concentrating O
on O
the O
direct O
association O
of O
the O
serum O
metabolite O
profiles O
of O
BC O
and O
the O
histopathology O
of O
bladder O
tissue, O
a O
composite O
panel O
of O
potential O
biomarkers O
including O
inosine, O
AFMK O
and O
LPS B-lipid
O-18:0/0:0 I-lipid
was O
identified O
as O
a O
diagnostic O
tool, O
which O
could O
precisely O
distinguish O
not O
only O
between O
HG O
BC O
and O
LG O
BC O
but O
also O
between O
LG O
BC O
and O
healthy O
control. O

ROC O
of O
MG B-lipid
18:2, I-lipid
Glycerophospho-N-Oleoyl O
Ethanolamine, O
PE B-lipid
18:2 I-lipid
and O
ZS O
in O
the O
prediction O
of O
patients O
with O
bicuspid O
aortic O
valve O
in O
estimation O
(a) O
and O
validation O
(b) O
groups. O

Highest O
mean O
concentrations O
were O
detected O
for O
polyunsaturated O
species O
with O
more O
than O
two O
double O
bonds: O
DG B-lipid
36:3, I-lipid
DG B-lipid
36:4, I-lipid
TG B-lipid
54:3, I-lipid
TG B-lipid
54:4, I-lipid
and O
TG B-lipid
54:5. I-lipid

LPC B-lipid
18:1 I-lipid
and O
PC B-lipid
36:2 I-lipid
were O
inversely O
associated O
with O
change O
in O
glucose, O
and O
SM O
36:0 O
and O
SM(1) B-lipid
18:0;3OH/24:0 I-lipid
were O
directly O
associated O
with O
change O
in O
glucose. O

Scatter O
plots O
are O
shown O
for O
total O
GM3 O
(A), O
and O
for O
the O
GM3 O
species O
GM3 B-lipid
18:1;O2/24:1 I-lipid
(B) O
and O
GM3 B-lipid
18:1;O2/26:0 I-lipid
(C). O

In O
a O
previous O
study, O
a O
shotgun O
lipid O
analysis O
incorporated O
with O
the O
PB O
reaction O
revealed O
significant O
changes O
in O
the O
C=C O
isomer O
compositions O
of O
C18:1 O
(Δ9/Δ11) O
for O
PC B-lipid
18:0_18:1 I-lipid
and O
PC B-lipid
18:1_18:1. I-lipid

Five O
compounds O
were O
identified O
in O
three O
classes O
of O
lipids: O
sphingolipids O
(sphinganine, O
Galα1-3(Fucα1-2)Galβ1-4Glcβ-Cer(d18:1/16:0)), O
endocannabinoids O
(docosatetraenoylethanolamide O
[DEA]), O
and O
glycerophospholipids O
(PE O
18:2(9Z,12Z)/0:0) O
and O
LPC B-lipid
18:1(9Z)/0:0). I-lipid

After O
the O
3-year O
follow-up, O
the O
control O
group O
showed O
significant O
decreases O
in O
the O
following O
12 O
metabolites: O
lysophosphatidylcholines O
(lysoPCs) O
containing O
C14:0, O
C16:1, O
C16:0, O
C17:0, O
C18:1, O
C18:0, O
C20:4, O
C20:3, O
and O
C22:6 O
(Suppl. O
1), O
PC B-lipid
16:0/18:1, I-lipid
PC B-lipid
18:0/18:2, I-lipid
and O
PC B-lipid
18:0/20:4. I-lipid

Fatty O
acids O
and O
their O
esters O
(e.g. O
FA B-lipid
18:0, I-lipid
FA B-lipid
17:0, I-lipid
FA B-lipid
14:0, I-lipid
FA B-lipid
20:0, I-lipid
cis O
vaccenic O
acid) O
showed O
altered O
levels O
in O
breast O
cancer O
patients O
in O
our O
study. O

Two O
sample O
preparation O
methodologies O
were O
used O
and O
validated O
for O
the O
analysis O
of O
AA, O
FA B-lipid
20:4;OH, I-lipid
FA O
20:4;OH, O
FA O
20:4;OH, O
11(12)-DiHETE O
and O
14(15)-DiHETE O
in O
plasma. O

For O
example, O
the O
decrease O
in O
the O
fatty O
acids O
18:3 O
and O
20:3 O
with O
fish O
oil O
supplementation O
as O
determined O
by O
GC-MS O
is O
consistent O
with O
the O
decrease O
of O
PC B-lipid
36:3 I-lipid
and O
PC B-lipid
38:3 I-lipid
if O
one O
assumes O
that O
one O
of O
the O
fatty O
acids O
in O
these O
species O
is O
the O
highly O
abundant O
palmitate O
(16:0—Fig. O

MTBE O
extraction O
also O
resulted O
in O
improved O
recovery O
of O
15:0 O
PC O
(p=0.00136), O
PC B-lipid
19:0/15:1 I-lipid
(p<0.001) O
and O
17:0 O
Cer O
(p=0.00173) O
compared O
to O
methanol. O

For O
processed O
samples O
(autosampler O
stability), O
the O
Cer B-lipid
22:0;O2 I-lipid
and O
Cer B-lipid
24:0;O2 I-lipid
were O
stable O
for O
3 O
days O
at O
room O
temperature. O

Calibration O
standards O
were O
prepared O
by O
spiking O
Cer B-lipid
22:0;O2 I-lipid
and O
Cer B-lipid
24:0;O2 I-lipid
working O
solution O
into O
5% O
BSA O
in O
water O
and O
plasma, O
to O
the O
final O
concentrations O
consisting O
of O
Cer O
22:0;O2 O
and O
Cer O
24:0;O2 O
at O
0.02/0.08, O
0.05/0.2, O
0.1/0.4, O
0.2/0.8, O
0.5/2, O
1/4, O
2/8, O
4/16 O
μg/mL, O
respectively, O
by O
serial O
dilution. O

PC B-lipid
28:1, I-lipid
PC B-lipid
30:2 I-lipid
and O
PC B-lipid
38:0 I-lipid
for O
which O
CLR O
estimated O
considerably O
lower O
most-probable O
concentrations O
than O
Biocrates; O
2). O

JWH-073 O
hydroxyindole, O
JWH-200 O
5-hydroxyindole, O
and O
JWH-210 O
FA B-lipid
5:0 I-lipid
were O
not O
detected, O
even O
when O
samples O
contained O
other O
metabolites O
originating O
from O
the O
same O
parent O
compound. O

In O
the O
m O
/z O
region O
of O
sn O
-1 O
fragment O
ions, O
detection O
of O
ions O
at O
m O
/z O
391 O
(sn O
-1 O
14:0), O
m O
/z O
405 O
(sn O
-1 O
15:0), O
and O
m O
/z O
419 O
(sn O
-1 O
16:0) O
proved O
that O
PC B-lipid
30:0 I-lipid
contained O
three O
molecular O
species: O
PC B-lipid
14:0/16:0, I-lipid
PC B-lipid
16:0/14:0, I-lipid
and O
PC B-lipid
15:0/15:0. I-lipid

TAG O
profiles O
in O
human O
and O
monkey O
plasma O
demonstrated O
that O
monkey O
plasma O
contained O
higher O
levels O
of O
TG B-lipid
52:5, I-lipid
52:4, O
56:8, O
56:7, O
56:6, O
58:10, O
58:9, O
58:8, O
58:7 O
and O
58:6. O

Interestingly, O
after O
the O
use O
of O
NRI, O
IDI, O
and O
Hosmer-Lemeshow O
test, O
the O
statistics O
indicated O
that O
LPC B-lipid
20:4 I-lipid
significantly O
improves O
prediction O
capacities O
of O
combined O
ABCD2 O
and O
LAA O
scores. O

Correlation O
and O
partition O
analysis O
along O
with O
Formal O
Concept O
Analysis O
(FCA) O
have O
identified O
that O
PC B-lipid
39:6 I-lipid
and O
FA B-lipid
22:3 I-lipid
could O
classify O
samples O
with O
higher O
certainty. O

IS O
 = 0.6 ± 0.4, O
N = 6) O
for O
relative O
quantitation O
of O
PE B-lipid
16:0_18:1. I-lipid

The O
Cer B-lipid
22:0;O2 I-lipid
and O
Cer B-lipid
24:0;O2 I-lipid
were O
determined O
to O
be O
stable O
for O
38 O
days O
at O
−80 O
°C. O

We O
examined O
the O
presence O
of O
mRNAs O
encoding O
4 O
human O
CYP450 O
isoforms O
that O
mediate O
FA B-lipid
20:4;OH I-lipid
production: O
CYP4A11, O
CYP4A22, O
CYP4F2 O
and O
CYP4F3 O
in O
eight O
different O
human O
cancer O
tissue O
samples O
(breast, O
colon, O
kidney, O
liver, O
lung, O
ovary, O
prostate O
and O
thyroid). O

We O
putatively O
characterized O
PC B-lipid
44:9, I-lipid
which O
is O
observed O
only O
as O
its O
potassium O
adduct, O
and O
we O
could O
therefore O
not O
include O
it O
into O
our O
prediction O
model O
in O
. O

The O
abnormal O
levels O
of O
the O
fatty O
acids O
(linolenic O
acid, O
linoleic O
acid, O
oleic O
acid, O
and O
arachidonic O
acid) O
and O
lysoPCs O
(lysoPC O
(14:0), O
LPC B-lipid
16:0, I-lipid
lysoPC O
(16:1), O
lysoPC O
(18:0) O
and O
lysoPC O
(20:3)) O
in O
ESCC O
patients O
are O
indicative O
of O
disturbed O
lipid O
and O
energy O
metabolism. O

In O
this O
metabolomics O
study, O
16 O
serum O
metabolites O
was O
found O
to O
be O
able O
to O
distinguish O
the O
GC O
patients O
from O
the O
healthy O
controls O
and O
3 O
serum O
metabolites O
(FA O
6:2(2,4), I-lipid
4-methylphenyl O
dodecanoate O
and O
glycerol O
tributanoate) O
of O
fatty O
acid O
pathways O
may O
be O
independent O
prognostic O
factors O
of O
GC, O
which O
might O
be O
of O
great O
beneficial O
for O
the O
early O
diagnosis O
and O
management O
of O
GC. O

Metabolites O
in O
GSH O
biosynthesis O
and O
methionine O
metabolism O
e.g., O
cysteine, O
FA B-lipid
4:0;2OH, I-lipid
and O
oxoproline, O
were O
significantly O
different O
in O
WD. O

The O
linoleate O
metabolites O
FA B-lipid
18:2;OH I-lipid
+ O
FA O
18:2;OH O
were O
also O
significantly O
higher O
in O
C-3N O
subjects. O

Statistically O
significant O
correlation O
was O
observed O
between O
plasma O
FA B-lipid
20:4;OH I-lipid
and O
PRA O
either O
when O
all O
of O
the O
studied O
subjects O
were O
considered O
(n=30) O
or O
when O
only O
data O
from O
patients O
with O
RVD O
were O
analyzed. O

As O
shown O
in O
Table O
, O
these O
included O
lysophosphatidylcholines O
(LPCs) O
[LPC O
16:0, I-lipid
LPC B-lipid
18:0, I-lipid
LPC B-lipid
18:2], I-lipid
lysophosphatidylethanolamines O
(LPEs) O
[LPE O
20:0], I-lipid
PC B-lipid
34:2, I-lipid
LPC B-lipid
O-16:0/0:0, I-lipid
PC B-lipid
36:2, I-lipid
PC B-lipid
32:0, I-lipid
PC B-lipid
36:3, I-lipid
PC B-lipid
38:4, I-lipid
PC B-lipid
34:1 I-lipid
and O
SM B-lipid
16:0;O2. I-lipid

Of O
these, O
the O
following O
four O
metabolites O
were O
finally O
selected O
as O
biomarker O
candidates O
by O
cross-validation: O
FA B-lipid
9:0, I-lipid
glucose, O
galactose, O
and O
cysteine O
+ O
cystine. O

In O
the O
H O
group, O
the O
abundant O
metabolites O
were O
mainly O
sugars O
(maltose, O
fructose), O
sugar O
alcohols, O
amines O
(galactosamine) O
and O
a O
large O
set O
of O
organic O
and O
fatty O
acids O
(glycerol, O
FA B-lipid
18:0, I-lipid
FA B-lipid
5:0;COOH, I-lipid
benezenepropanoic O
acid, O
linoleic O
acid, O
and O
oleic O
acid). O

After O
the O
3-year O
follow-up, O
the O
control O
group O
showed O
significant O
decreases O
in O
the O
following O
12 O
metabolites: O
lysophosphatidylcholines O
(lysoPCs) O
containing O
C14:0, O
C16:1, O
C16:0, O
C17:0, O
C18:1, O
C18:0, O
C20:4, O
C20:3, O
and O
C22:6 O
(Suppl. O
1), O
PC B-lipid
16:0/18:1, I-lipid
PC B-lipid
18:0/18:2, I-lipid
and O
PC B-lipid
18:0/20:4. I-lipid

Sphinganine O
d18:0 O
(Sa), O
Sphinganine-1-phosphate O
(Sa1P), O
sphingosine O
d18:1 O
(So), O
sphingosine-1-phosphate O
(So1P), O
Cer B-lipid
18:1;O2/16:0 I-lipid
(C16Cer), O
Cer B-lipid
18:1;O2/18:0 I-lipid
(C18Cer), O
Cer B-lipid
18:1;O2/22:0 I-lipid
(C22Cer), O
Cer B-lipid
18:1;O2/24:0 I-lipid
(C24Cer), O
Cer O
18:1;O2/16:0 O
(C16Cer), O
dihydroceramide O
(d18:1/16:1) O
(C16dHCer), O
dihydroceramide O
(d18:1/24:1), O
glucosylceramide O
(d18:1/16:0) O
(C16GlcCer), O
ISs O
Sphinganine O
d17:0 O

iPF_2a O
IV (P O
 = 0.021), O
FA B-lipid
20:3;Ep I-lipid
(P O
 = 0.040), O
FA B-lipid
20:4;OH I-lipid
(P O
 = 0.019), O
FA B-lipid
20:3;(OH)2 I-lipid
(P O
 = 0.017) O
and O
FA B-lipid
22:6;OH I-lipid
(P O
 = 0.033). O

The O
later O
eluting O
isomer O
of O
PC B-lipid
40:6 I-lipid
coeluted O
with O
our O
standard, O
PC B-lipid
18:0/22:6. I-lipid

Elevated O
serum O
levels O
of O
FA B-lipid
20:5 I-lipid
observed O
in O
the O
current O
work O
may O
similarly O
reflect O
its O
restricted O
conversion O
to O
anti-inflammatory O
DHA-derived O
lipid O
mediators O
in O
obese O
NASH. O

Extracted O
ion O
chromatograms O
from O
LC-MRM-MS O
analysis O
of O
19-HETE O
and O
FA B-lipid
20:4;OH I-lipid
(A), O
FA B-lipid
20:3;Ep I-lipid
and O
FA O
20:3;Ep O
(B) O
monitored O
at O
different O
transitions. O

